"country","first_author","source_name","estimate_grade","source_type","state","city","study_inclusion_criteria","study_exclusion_criteria","sex","sampling_start_date","sampling_end_date","population_group","age","denominator_value","serum_pos_prevalence","seroprev_95_ci_lower","seroprev_95_ci_upper","sampling_method","test_name","test_manufacturer","test_type","isotypes","antibody_target","test_validation","sensitivity","specificity","url","remarks"
"Albania","Genc Sulcebe","Rapid increase of SARS-CoV-2 seroprevalence during the second half of the COVID-19 pandemic year 2020 in the adult urban Albanian population.","Local","Journal Article (Peer-Reviewed)",NA,"Tirana","This study aims to fill this gap by providing data on the changes in COVID-19 seroprevalence among the adult urban population of Albania between July and December 2020, using two independent, randomly selected samples of individuals aged 20–70 years who reside in Metropolitan Tirana, which represents approximately one-third of Albania’s urban population [9].",NA,"All","2020-12-21","2020-12-28","Household and community samples","Adults (18-64 years)",815,0.482,0.448,0.517,"Stratified probability","Anti-SARS-CoV-2 ELISA IgG","EUROIMMUN","ELISA","IgG","Spike","Validated by manufacturers",0.944,0.996,"https://dx.doi.org/10.1016/j.heliyon.2023.e19547","No asymptomatics"
"Argentina","Universidad Nacional De Hurlingham","Se presentaron los resultados del estudio de seroprevalencia de COVID-19 que realizó la Universidad en el Municipio de Hurlingham","Local","Institutional Report","Buenos Aires","Buenos Aires","The tests were carried out using a drop of blood taken from people's homes",NA,"All","2020-12-01","2020-12-30","Household and community samples","Multiple groups",1182,0.121,0.1,0.142,"Stratified probability","SEROKIT-ELISA COVIDAR IgG","COVIDAR","ELISA","IgG",NA,NA,NA,NA,"http://www.unahur.edu.ar/es/se-presentaron-los-resultados-del-estudio-de-seroprevalencia-de-covid-19-que-realizo-la-universidad","Institutional report"
"Argentina","Government of the Province of Buenos Aires","ONLY 13 PERCENT OF THE
  NEIGHBOURS OF 30 PEOPLE'S NEIGHBOURHOODS OF THE AMBA HAD CORONAVIRUS","Local","News and Media","Buenos Aires","Metropolitan Area of Buenos Aires",NA,NA,"All","2020-07-15","2020-12-15","Household and community samples","Multiple groups",9000,0.13,NA,NA,"Unclear","Not reported/ Unable to specify",NA,"ELISA",NA,NA,NA,NA,NA,"https://www.gba.gob.ar/saludprovincia/noticias/s%C3%B3lo_el_13_por_ciento_de_los_vecinos_y_vecinas_de_30_barrios_populares_del","News and media"
"Argentina","Luz Maria Rodeles","Seroprevalence of anti-SARS-CoV-2 IgG in asymptomatic and pauci-symptomatic people over a 5 month survey in Argentina.","Local","Journal Article (Peer-Reviewed)",NA,"Santa Fe","""Volunteers over 18 years of age, of both sexes, residents from the different districts of the city were included""","""Individuals previously diagnosed with COVID-19 clinically and/or
by laboratory tests (RT-PCR, antigen detection, or antibodies
test) were excluded according to the criteria of suspected cases
throughout the study period., we We also excluded people who
had been in close contact with confirmed or suspected cases 20 days before taking the sample, if they developed symptoms
attributable to COVID-19.""","All","2020-07-01","2020-11-30","Multiple general populations","Multiple groups",3000,0.0883,NA,NA,"Convenience","SEROKIT-ELISA COVIDAR IgG","COVIDAR","ELISA","IgG","Spike","Validated by independent authors/third party/non-developers",0.967,1,"https://dx.doi.org/10.26633/RPSP.2021.66","No representation"
"Austria","Marie Kathrin Breyer","Low SARS-CoV-2 seroprevalence in the Austrian capital after an early governmental lockdown.","Local","Journal Article (Peer-Reviewed)",NA,"Vienna","Individuals in the LEAD study cohort and their household members.
(The LEAD study cohort is a general population cohort providing a representative sample of the general Viennese population in terms of age, sex, smoking habits, and place of residence.)",NA,"All","2020-04-20","2020-05-20","Household and community samples","Multiple groups",12419,0.0131,NA,NA,"Stratified probability","Elecsys® Anti‐SARS‐CoV‐2 (S),Anti-SARS-CoV-2 ELISA IgG,Author designed (Neutralization Assay)","Roche Diagnostics,EUROIMMUN,NA","Multiple Types","['IgG', 'Neutralizing']","Spike",NA,NA,NA,"https://dx.doi.org/10.1038/s41598-021-89711-5","No asymptomatics"
"Austria","Dennis Ladage","SARS-CoV-2-Specific Antibody Prevalence and Symptoms in a Local Austrian Population","Local","Journal Article (Peer-Reviewed)","Lower Austria","Weißenkirchen",NA,NA,"All","2020-06-01","2020-06-30","Household and community samples","Multiple groups",835,0.085,NA,NA,"Convenience","Anti-SARS-CoV-2 ELISA IgG","EUROIMMUN","ELISA","IgG","Spike",NA,NA,NA,"http://dx.doi.org/10.3389/fmed.2021.632942","No phi_c"
"Austria","Ludwig Knabl","High SARS-CoV-2 seroprevalence in children and adults in the Austrian ski resort of Ischgl","Local","Journal Article (Peer-Reviewed)","Tyrol","Ischgl","This cross-sectional epidemiological survey targeted all
residents of Ischgl/Tyrol irrespective of age and gender","""After exclusion of 61 study participants (due to missing of one of the biosamples, i.e., blood sampling was not possible in 2 children and 59 adults refused swab sampling), 1473 (79% of the Ischgl population) were included in our statistical
analysis.""

Missing of one of the biosamples, i.e., blood sampling was
not possible in 2 children and 59 adults refused swab sampling","All","2020-04-21","2020-04-27","Household and community samples","Multiple groups",1473,0.424,0.398,0.447,"Self-referral","Anti-SARS-CoV-2 ELISA IgG,Anti-SARS-CoV-2 ELISA IgA,Abbott Architect SARS-CoV-2 IgG,Author designed (Neutralization Assay)","EUROIMMUN,Abbott Laboratories,NA","Multiple Types","['IgA', 'IgG']","['Nucleocapsid(N-protein)', 'Spike']",NA,NA,NA,"https://www.nature.com/articles/s43856-021-00007-1?error=cookies_not_supported&code=8b72864e-3eb4-4c31-bdd1-924a657e6b28","No phi_c"
"Austria","Wegene Borena","Persistence of immunity to SARS-CoV-2 over time in the ski resort Ischgl","Local","Journal Article (Peer-Reviewed)","Tyrol","Ischgl","Adults in ski resort Ischgl in Austria",NA,"All","2020-11-02","2020-11-08","Household and community samples","Adults (18-64 years)",801,0.454,0.42,0.49,"Convenience","Anti-SARS-CoV-2 ELISA IgA,Anti-SARS-CoV-2 ELISA IgG,Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N),Author designed (Neutralization Assay)","EUROIMMUN,Abbott Laboratories,Roche Diagnostics,NA","Multiple Types","['IgA', 'IgG']","Spike","Multiple tests with diff validations or values derived from each type",NA,NA,"https://dx.doi.org/10.1016/j.ebiom.2021.103534","No asymptomatics"
"Belgium","Celine Gregoire","Predictive factors for the presence and long-term persistence of SARS-CoV-2 antibodies in healthcare and university workers","Local","Journal Article (Peer-Reviewed)",NA,"Liege","Based on another article of the same study (https://airtable.com/appFfYIupTrVQ0HJx/tbl9ldV2170ox2BWJ/viwebfDZuM4u8mSwH/recoCT3RvB4Y0eAKx?blocks=hide):

""Workers of the University Hospital Center (CHU) of Liège across all
sites and of the University of Liège (ULiège) on the Sart-Tilman site were invited to participate.""","Based on another article of the same study (https://airtable.com/appFfYIupTrVQ0HJx/tbl9ldV2170ox2BWJ/viwebfDZuM4u8mSwH/recoCT3RvB4Y0eAKx?blocks=hide):

""When suspected of COVID-19 within 14 days before testing"".","All","2020-04-06","2020-05-05","Multiple populations","Multiple groups",3776,0.089,NA,NA,"Convenience","Liaison SARS-CoV-2 S1/S2 IgG","DiaSorin","CLIA","IgG","Spike","Validated by independent authors/third party/non-developers",1,0.979,"https://doi.org/10.1038/s41598-022-13450-4","No representation"
"Cameroon","Kene Nwosu","SARS-CoV-2 antibody seroprevalence and associated risk factors in an urban district in Cameroon.","Local","Journal Article (Peer-Reviewed)","Centre","Yaoundé","In each household, all individuals between five and 80 years of age were included if they (a) had been present in the household for at least 14 days prior to the survey, and (b) could give written informed consent (or had an adult guardian who could give consent).",NA,"All","2020-10-14","2020-11-26","Household and community samples","Multiple groups",971,0.292,0.238,0.349,"Simplified probability","Panbio COVID-19 IgG/IgM rapid test device","Abbott Laboratories","LFIA","IgG","Nucleocapsid(N-protein)","Validated by independent authors/third party/non-developers",0.915,0.935,"https://dx.doi.org/10.1038/s41467-021-25946-0","Included"
"Congo","Armel Batchi Bouyou","High SARS-COV2 IgG/IGM seroprevalence in asymptomatic Congolese in Brazzaville, the Republic of Congo","Local","Journal Article (Peer-Reviewed)",NA,"Brazzaville","Only individuals without any disease symptom, aged more than 18 years old and giving a written consent were enrolled. The participants were resident of all the districts of Brazzaville",NA,"All","2020-04-01","2020-07-31","Household and community samples","Adults (18-64 years)",754,0.197,NA,NA,"Self-referral","UNSCIENCE COVID-19 IgG/IgM antibody Rapid Test Kit,Sienna-Clarity COVIBLOCK COVID-19 IgG/IgM Rapid Test Cassette","Wuhan UNscience Biotechnology Co. Ltd,Salofa Oy","LFIA","['IgG', 'IgM']",NA,NA,NA,NA,"https://dx.doi.org/10.1016/j.ijid.2020.12.065","No representation"
"Democratic Republic of the Congo","Philippe Bianga Katchunga","Seroprevalence of SARS-CoV-2 antibodies among travellers and workers screened at the saint luc clinic in Bukavu, a city in eastern democratic Republic of the Congo, from may to august 2020","Local","Journal Article (Peer-Reviewed)",NA,"Bukavu","Any subject, regardless of age, sex and origin was eligible for voluntary serological screening for SARS-CoV-2.",NA,"All","2020-05-15","2020-08-30","Multiple populations","Multiple groups",684,0.4079,NA,NA,"Self-referral","COVID-19 IgG/IgM Rapid Test Cassette","Cellex Inc.","LFIA","['IgG', 'IgM']",NA,"Validated by manufacturers",0.938,0.96,"https://www.panafrican-med-journal.com/content/article/38/93/full/","No representation"
"Democratic Republic of the Congo","Antoine Nkuba","High prevalence of anti-SARS-CoV-2 antibodies after the first wave of COVID-19 in Kinshasa, Democratic Republic of the Congo: results of a cross-sectional household-based survey.","Local","Journal Article (Peer-Reviewed)",NA,"Kinshasa","all the residents were invited to participate in the study in 50% of households and among the
remaining 50%, only the residents aged 18 years and older were invited to participate",NA,"All","2020-10-22","2020-11-08","Household and community samples","Multiple groups",1080,0.166,0.14,0.195,"Stratified probability","Author designed (Luminex)",NA,"CLIA","IgG","['Nucleocapsid(N-protein)', 'Spike']","Validated by developers",1,0.997,"https://dx.doi.org/10.1093/cid/ciab515","No representation"
"Ecuador","Oscar Del Brutto","SARS-CoV-2 in rural Latin America. A population-based study in coastal Ecuador","Local","Journal Article (Peer-Reviewed)","El Oro",NA,"Members of the Atahualpa cohort project, ongoing since 2012 - adults over 40 years old and reside in the village of Atahualpa, Ecuador",NA,"All","2020-05-01","2020-05-25","Household and community samples","Multiple groups",673,0.45,NA,NA,"Convenience","BIOHIT SARS-CoV-2 antibody test","Biohit Health Care Ltd","LFIA","['IgG', 'IgM']",NA,NA,NA,NA,"http://dx.doi.org/10.1093/cid/ciaa1055","No representation"
"Ecuador","David Acurio Paez","Seroprevalence of SARS-CoV-2 Infection and Adherence to Preventive Measures in Cuenca, Ecuador, October 2020, a Cross-Sectional Study","Local","Journal Article (Peer-Reviewed)","Azuay",NA,"Individuals living in rural or urban areas of Cuenca",NA,"All","2020-08-11","2020-11-01","Household and community samples","Multiple groups",2457,0.132,NA,NA,"Stratified probability","Standard Q COVID-19 IgM/IgG Duo rapid immunochromatography test kit","SD Biosensor","LFIA","['IgG', 'IgM']",NA,"Validated by manufacturers",0.879,0.943,"https://www.mdpi.com/1660-4601/18/9/4657","No asymptomatics"
"Egypt","Sherief Musa","Prevalence of SARS-CoV-2 infection and dynamics of antibodies response among previously undiagnosed healthcare workers in a university hospital: A prospective cohort study.","Local","Journal Article (Peer-Reviewed)",NA,"Cairo","Non-healthcare workers (NHCWs) were recruited randomly as volunteers not affiliated to any healthcare facility","Individuals previously tested positive for SARS-CoV-2 via RT-PCR or those self-isolating at home due to symptoms typical of COVID-19 during the last 14 days were excluded from the study.","All","2020-06-01","2020-06-14","Household and community samples","Adults (18-64 years)",725,0.294,NA,NA,"Simplified probability","VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total","Ortho Clinical Diagnostics Inc.","CLIA","TotalAntibody","Spike","Validated by manufacturers",0.9,1,"https://dx.doi.org/10.1016/j.jiph.2021.06.001","No asymptomatics"
"Egypt","Amira S. El Rifay","Determinants of having severe acute respiratory syndrome coronavirus 2 neutralizing antibodies in Egypt.","Local","Journal Article (Peer-Reviewed)",NA,"Cairo","The study population was employees of a major research institution in
Egypt located in Greater Cairo, totaling around 7000.9 In the period
August–October 2020, study personnel visited all departments of the
institution on two different days and invited all individuals present at
the time of the visit and who never had a laboratory-confirmed SARSCoV-2 infection to participate.","Research institution employees who have had a laboratory-confirmed SARSCoV-2 infection.","All","2020-08-15","2020-10-15","Multiple general populations","Multiple groups",888,0.3,NA,NA,"Convenience","Author designed (Neutralization Assay)",NA,"Neutralization",NA,NA,NA,NA,NA,"https://dx.doi.org/10.1111/irv.12889","No asymptomatics"
"Ethiopia","Saro Abdella","Prevalence of SARS-CoV-2 in urban and rural Ethiopia: Randomized household serosurveys reveal level of spread during the first wave of the pandemic","Local","Journal Article (Peer-Reviewed)","Oromia Region","Addis Ababa","one participant per household in Addis Ababa, aged 18 or above, was chosen at random for antibody testing",NA,"All","2020-07-22","2020-09-02","Household and community samples","Multiple groups",956,0.035,0.017,0.054,"Stratified probability","Coretests COVID-19 IgM/IgG Ab Test","Core Technology Co. Ltd","LFIA","['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']","Validated by independent authors/third party/non-developers",0.69,0.97,"http://dx.doi.org/10.1016/j.eclinm.2021.100880","No asymptomatics"
"Ethiopia","Tamrat Shaweno","Seroprevalence of SARS-CoV-2 antibody among individuals aged above 15 years and residing in congregate settings in Dire Dawa city administration, Ethiopia.","Local","Journal Article (Peer-Reviewed)",NA,"Dire Dawa city","SARS-CoV-2 serosurvey was conducted among individuals aged above 15 years and residing in randomly selected households from purposively selected 11 enumeration areas in overcrowded neighborhoods.","Sixty-six (66) samples were not included into this analysis due to grossly hemolyzed specimens 21 (3.8%), information mismatch on request form 14 (2.1%), insufficient specimen volume 18 (2.7%), and missing labels on container 13 (2.0%).","All","2020-06-15","2020-07-30","Household and community samples","Multiple groups",684,0.032,0.02,0.048,"Simplified probability","Abbott Architect SARS-CoV-2 IgG","Abbott Laboratories","CLIA","IgG","Nucleocapsid(N-protein)","Validated by manufacturers",1,0.996,"https://dx.doi.org/10.1186/s41182-021-00347-7","No representation"
"Georgia","Tengiz Tsertsvadze","SARS-CoV-2 antibody seroprevalence in Tbilisi, the capital city of country of Georgia","Local","Preprint","Tbilisi","Tbilisi","Eligibility criteria included age 18 years old, no confirmed SARS-CoV-2 infection and no current symptoms consistent with COVID-19.",NA,"All","2020-05-18","2020-05-27","Household and community samples","Multiple groups",1086,0.0102,0.0038,0.0218,"Convenience","COVID-19 IgG/IgM Rapid Test","Zhejiang Orient Gene Biotech","LFIA","IgG",NA,"Validated by independent authors/third party/non-developers",0.931,0.992,"https://www.medrxiv.org/content/10.1101/2020.09.18.20195024v1","Preprint"
"Germany","Peter Kern","Studie zur immunitat gegen sars-cov-2","Local","Journal Article (Peer-Reviewed)",NA,"Fulda","Hospital employees with direct patient contact or employees of local supermarkets with direct customer contact",NA,"All","2020-04-09","2020-04-16","Multiple populations","Multiple groups",1780,0.00955,0.00557,0.01525,"Unclear","Anti-SARS-CoV-2 ELISA IgA","EUROIMMUN","ELISA","IgG","Spike","Validated by independent authors/third party/non-developers",0.938,0.99,"http://dx.doi.org/10.1055/a-1198-1243","No english"
"Germany","Sebastian Weis","Seroprevalence of SARS-CoV-2 antibodies in an entirely PCR-sampled and quarantined community after a COVID-19 outbreak - the CoNAN study","Local","Preprint","Thuringia",NA,"All inhabitants of the community of Neustadt-am-Rennsteig regardless of age, gender or infections status were eligible for participation.","Individuals that do not reside in Neustadt-am-Rennsteig or that live in the adjacent community of Kahlert were not eligible for inclusion.","All","2020-05-12","2020-05-22","Household and community samples","Multiple groups",620,0.0839,NA,NA,"Convenience","EDI™ Novel Coronavirus COVID-19 IgM ELISA Kit,MAGLUMI 2019-nCoV IgM/IgG,Liaison SARS-CoV-2 S1/S2 IgG,Abbott Architect SARS-CoV-2 IgG,Anti-SARS-CoV-2 ELISA IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Epitope Diagnostics, Inc.,Snibe Co. Ltd (Shenzhen New Industries Biomedical Engineering Co. Ltd),DiaSorin,Abbott Laboratories,EUROIMMUN,Roche Diagnostics","Multiple Types","IgG","['Nucleocapsid(N-protein)', 'Spike']",NA,NA,NA,"https://www.medrxiv.org/content/10.1101/2020.07.15.20154112v1","Better study available"
"Germany","Hendrik Streeck","Infection fatality rate of SARS-CoV2 in a super-spreading event in Germany","Local","Journal Article (Peer-Reviewed)","Heinsberg","Gangelt","For this cross-sectional epidemiological study, all inhabitants of Gangelt were eligible.

Sample of 600 persons aged older than 18 was drawn from a civil register, and family members of each individual was invited to participate",NA,"All","2020-03-31","2020-04-06","Household and community samples","Multiple groups",919,0.1411,0.1115,0.1727,"Simplified probability","Anti-SARS-CoV-2 ELISA IgG","EUROIMMUN","ELISA","IgG",NA,"Validated by manufacturers",0.909,0.991,"https://www.nature.com/articles/s41467-020-19509-y","Better study available"
"Germany","Sebastian Weis","Antibody response using six different serological assays in a completely PCR-tested community after a COVID-19 outbreak - The CoNAN study.","Local","Journal Article (Peer-Reviewed)","Thuringia",NA,"Participants were enrolled from 13 May to 16 May
2020 at a central study site, set-up in the village town hall. Participants who could not come to the study site were enrolled by the local primary care physician at their respective homes until the 22 May. The sample size of the CoNAN-cohort is fixed by the number of inhabitants of the community. We aimed to include the population as completely as possible.","Individuals that did not reside in Neustadt am Rennsteig or that lived in the adjacent community of Kahlert were not eligible forinclusion","All","2020-05-13","2020-05-16","Household and community samples","Multiple groups",620,0.084,NA,NA,"Self-referral","EDI™ Novel Coronavirus COVID-19 IgM ELISA Kit,MAGLUMI 2019-nCoV IgM/IgG,Liaison SARS-CoV-2 S1/S2 IgG,Abbott Architect SARS-CoV-2 IgG,Anti-SARS-CoV-2 ELISA IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Epitope Diagnostics, Inc.,Snibe Co. Ltd (Shenzhen New Industries Biomedical Engineering Co. Ltd),DiaSorin,Abbott Laboratories,EUROIMMUN,Roche Diagnostics","Multiple Types","IgG","['Nucleocapsid(N-protein)', 'Spike', 'Whole-virusantigen']",NA,NA,NA,"https://dx.doi.org/10.1016/j.cmi.2020.11.009","Better study available"
"Germany","Claudia Santos Hovener","Serology- and PCR-based cumulative incidence of SARS-CoV-2 infection in adults in a successfully contained early hotspot (CoMoLo study), Germany, May to June 2020","Local","Journal Article (Peer-Reviewed)","Baden-Württemberg","Kupferzell","A random sample of 3,534 Kupferzell residents aged 18
years and older from the mandatory population registry
(68.9% of the 5,128 adult residents) was invited to take
part in the study,",NA,"All","2020-05-20","2020-06-09","Household and community samples","Multiple groups",2203,0.12,0.104,0.14,"Simplified probability","Anti-SARS-CoV-2 ELISA IgG","EUROIMMUN","ELISA","IgG","Spike","Validated by independent authors/third party/non-developers",0.883,0.992,"https://dx.doi.org/10.2807/1560-7917.ES.2020.25.47.2001752","Included"
"Germany","Robert Koch Institute","Corona monitoring locally - First key data for Bad Feilnbach","Local","News and Media",NA,"Bad Feilnbach",NA,NA,"All","2020-06-23","2020-07-04","Household and community samples","Multiple groups",2152,0.091,NA,NA,"Simplified probability","Not reported/ Unable to specify",NA,NA,"IgG",NA,NA,0.883,0.994,"https://www.rki.de/DE/Content/Gesundheitsmonitoring/Studien/cml-studie/Factsheet_Bad_Feilnbach.html","News and media"
"Germany","Robert Koch Institute","Corona monitoring locally -
  Key data for Straubing","Local","News and Media","Bavaria","Straubing","if they are 18 years or older, are registered residents of one of the four study municipalities, can provide written consent to participate in the study, or, where necessary, written consent is provided by a legal representative, are able to take part in the interviews (where necessary with the help of relatives) and the examinations at the
study centres or during home visits.","People who lack the necessary German language skills or where it is unclear whether they understand the study information leaflets or the consent forms are excluded from participating.","All","2020-09-08","2020-09-26","Household and community samples","Multiple groups",2361,0.017,NA,NA,"Simplified probability","Anti-SARS-CoV-2 ELISA IgG","EUROIMMUN","ELISA","IgG",NA,NA,0.883,0.994,"https://www.rki.de/DE/Content/Gesundheitsmonitoring/Studien/cml-studie/Factsheet_Straubing.html","News and media"
"Germany","Stefanie Theuring","SARS-CoV-2 infection and transmission in school settings during the second wave in Berlin, Germany: a cross-sectional study","Local","Preprint",NA,"Berlin","Household membrs related to participating students or staff from each one class in 24 schools in Berlin, and related household members",NA,"All","2020-11-02","2020-11-16","Household and community samples","Multiple groups",576,0.014,0.006,0.027,"Stratified probability","Not reported/ Unable to specify",NA,"ELISA","IgG",NA,NA,NA,NA,"https://www.medrxiv.org/content/10.1101/2021.01.27.21250517v1","No representation"
"Germany","Insa Backhaus","Seroprevalence COVID-19 Düsseldorf: SERODUS I & II","Local","Institutional Report",NA,"Düsseldorf","Main residence in Düsseldorf
- 18-30 years old
- Person is able to take part in the questioning and to
to participate in the investigation
- Knowledge of German, English, Turkish
or the Arabic language","Acute COVID-19 illness or equivalent
Symptoms (e.g. fever, cough)
- Unprotected contact with a COVID-19
Patients in the last 14 days and none of their own
negative COVID-19 test (i.e. PCR detection of
Virus DNA negative in revenge / nasal swab)
- Presence of coagulation diseases
- Person is unable to provide a written,
to give informed consent.
- Other reasons (e.g. not able to travel) related to this
lead that participation in survey and
Investigation is not possible","All","2020-11-02","2020-11-23","Household and community samples","Adults (18-64 years)",2186,0.031,0.024,0.04,"Simplified probability","Elecsys® Anti‐SARS‐CoV‐2 (N)","Roche Diagnostics","CLIA","['IgA', 'IgG', 'IgM']","Nucleocapsid(N-protein)","Validated by manufacturers",0.9,0.998,"https://www.uniklinik-duesseldorf.de/patienten-besucher/klinikeninstitutezentren/institut-fuer-medizinische-soziologie/das-institut/forschung/serodus","Institutional report"
"Germany","Robert Koch Institut","Corona monitoring locally -
  Key data for Berlin-Mitte","Local","News and Media","Berlin","Berlin-Mitte","if they are 18 years or older, are registered residents of one of the four study municipalities, can provide written consent to participate in the study, or, where necessary, written consent is provided by a legal representative, are able to take part in the interviews (where necessary with the help of relatives) and the examinations at the","People who lack the necessary German language skills or where it is unclear whether they understand the study information leaflets or the consent forms are excluded from participating","All","2020-11-17","2020-12-05","Household and community samples","Multiple groups",2287,0.044,NA,NA,"Simplified probability","Anti-SARS-CoV-2 ELISA IgG","EUROIMMUN","ELISA","IgG",NA,NA,NA,NA,"https://www.rki.de/DE/Content/Gesundheitsmonitoring/Studien/cml-studie/Factsheet_Berlin-Mitte.html","News and media"
"Germany","Franziska Hommes","Sars-cov-2 infection, risk perception, behaviour and preventive measures at schools in berlin, germany, during the early post-lockdown phase: A cross-sectional study","Local","Journal Article (Peer-Reviewed)",NA,"Berlin",NA,NA,"All","2020-06-11","2020-06-19","Multiple populations","Multiple groups",527,0.013,NA,NA,"Stratified non-probability","Anti-SARS-CoV-2 ELISA IgG","EUROIMMUN","ELISA","IgG",NA,NA,NA,NA,"http://dx.doi.org/10.3390/ijerph18052739","No representation"
"Germany","Michael Pritsch","Prevalence and Risk Factors of Infection in the Representative COVID-19 Cohort Munich","Local","Journal Article (Peer-Reviewed)","Bavaria","Munich","14 years or older.",NA,"All","2020-04-05","2020-06-12","Household and community samples","Multiple groups",5313,0.0182,0.0128,0.0237,"Stratified probability","Elecsys® Anti‐SARS‐CoV‐2 (N)","Roche Diagnostics","CLIA","TotalAntibody","Nucleocapsid(N-protein)","Validated by independent authors/third party/non-developers",0.886,0.9972,"https://dx.doi.org/10.3390/ijerph18073572","No asymptomatics"
"Germany","Ralf Wagner","Estimates and determinants of SARS-CoV-2 seroprevalence and infection fatality ratio using latent class analysis: the population-based Tirschenreuth study in the hardest-hit German county in spring 2020","Local","Preprint","Bavaria",NA,"Inclusion criteria were legal age and univalent consent of custodial
parents for those aged < 18 years, German language skills sufficiently good to understand the participant
information and to respond to the questionnaire","Children below 14 years and individuals with legal guardian
were excluded from participation.","All","2020-06-28","2020-07-10","Household and community samples","Multiple groups",4201,0.0864,NA,NA,"Simplified probability","iFlash-SARS-CoV-2 IgM/IgG,Elecsys® Anti‐SARS‐CoV‐2 (N),Author designed (ELISA) -Spike","Shenzhen Yhlo Biotech Co. Ltd,Roche Diagnostics,NA","Multiple Types","IgG","['Nucleocapsid(N-protein)', 'Spike']",NA,NA,NA,"https://www.medrxiv.org/content/10.1101/2021.03.29.21254343v1","No representation"
"Germany","N Ahmad Aziz","Seroprevalence and correlates of SARS-CoV-2 neutralizing antibodies from a population-based study in Bonn, Germany","Local","Journal Article (Peer-Reviewed)","North Rhine-Westphalia","Bonn","Participants who were already enrolled in the Rhineland study, aged 30 and above of two geographically defined areas until March 18, 2020","Insufficient command of the german language to provide informed consent.","All","2020-04-24","2020-06-30","Household and community samples","Multiple groups",4755,0.0097,0.0072,0.013,"Convenience","Anti-SARS-CoV-2 ELISA IgG","EUROIMMUN","ELISA","IgG",NA,"Validated by manufacturers",0.944,0.996,"https://dx.doi.org/10.1038/s41467-021-22351-5","No representation"
"Germany","Christine Klein","Cohort-based surveillance of SARS-CoV2 transmission mirrors infection rates at the population level a one-year longitudinal study","Local","Preprint",NA,"Lubeck","Adults in the Lubeck area",NA,"All","2020-05-06","2020-05-31","Household and community samples","Multiple groups",3051,0.0079,NA,NA,"Self-referral","Anti-SARS-CoV-2 ELISA IgG","EUROIMMUN","ELISA","IgG","Spike",NA,NA,NA,"https://www.medrxiv.org/content/10.1101/2021.05.10.21256966v1.full-text","Preprint"
"Germany","Stefanie Theuring","SARS-CoV-2 infection and transmission in school settings during the second COVID-19 wave: a cross-sectional study, Berlin, Germany, November 2020.","Local","Journal Article (Peer-Reviewed)",NA,"Berlin","In the first round in June, the proportion of students participating per class was 65% (range: 13–96). Hereafter, students and staff were considered index participants. In this second round in November, household members of index participants were also invited to participate.","Three schools unable to participate were replaced by randomly
resampled substitutes.","All","2020-11-02","2020-11-16","Household and community samples","Multiple groups",576,0.014,0.006,0.027,"Stratified probability","Anti-SARS-CoV-2 ELISA IgG","EUROIMMUN","ELISA","IgG",NA,NA,NA,NA,"https://dx.doi.org/10.2807/1560-7917.ES.2021.26.34.2100184","No representation"
"Germany","Felizitas Eichner","[Seroprevalence of COVID-19 and Psychosocial Effects in the General Population: Results of the STAAB-COVID-One Program].","Local","Journal Article (Peer-Reviewed)","Bavaria","Würzburg",NA,NA,"All","2020-06-01","2020-10-31","Household and community samples","Multiple groups",3034,0.011,0.00699999999999999,0.015,"Stratified non-probability","Elecsys® Anti‐SARS‐CoV‐2 (N)","Roche Diagnostics","CLIA","['IgA', 'IgG', 'IgM']","Nucleocapsid(N-protein)",NA,NA,NA,"https://dx.doi.org/10.1055/a-1630-7601","No english"
"Germany","Daniela Gornyk","SARS-CoV-2 Seroprevalence in Germany - A Population-Based Sequential Study in Seven Regions","Local","Journal Article (Peer-Reviewed)","North Rhine-Westphalia","Aachen","Residents of Aachen >18 years of age.","Vaccinated subjects","All","2020-09-09","2020-10-09","Household and community samples","Multiple groups",2023,0.02,0.01,0.029,"Simplified probability","Anti-SARS-CoV-2 ELISA IgG","EUROIMMUN","ELISA","IgG","Spike","Validated by independent authors/third party/non-developers",0.883,0.992,"https://dx.doi.org/10.3238/arztebl.m2021.0364","No asymptomatics"
"Germany","Christine Klein","One-year surveillance of SARS-CoV-2 transmission of the ELISA cohort: A model for population-based monitoring of infection risk","Local","Journal Article (Peer-Reviewed)","Schleswig-Holstein","Lubeck","""3000 people who represent ~1% of the population living in our catchment area, a major tourist region on the Baltic Sea in Northern Germany for the entire first year of the pandemic""",NA,"All","2020-11-16","2020-11-16","Household and community samples","Multiple groups",2547,0.0185,NA,NA,"Self-referral","Anti-SARS-CoV-2 ELISA IgG","EUROIMMUN","ELISA","IgG","Spike",NA,NA,NA,"https://dx.doi.org/10.1126/sciadv.abm5016","No asymptomatics"
"Germany","Enrico Richter","Analysis of fatality impact and seroprevalence surveys in a community sustaining a SARS-CoV-2 superspreading event.","Local","Journal Article (Peer-Reviewed)","North Rhine-Westphalia","Gangelt","Participants in Gangelt who participated in a previous study (https://doi.org/10.1038/s41467-020-19509-y) by the same authors",NA,"All","2020-10-01","2020-10-31","Household and community samples","Multiple groups",583,0.181,0.137,0.23,"Simplified probability","Anti-SARS-CoV-2 ELISA IgG","EUROIMMUN","ELISA","IgG","Spike","Validated by manufacturers",0.909,0.991,"https://dx.doi.org/10.1038/s41598-023-32441-7","No asymptomatics"
"Germany","Ronan Le Gleut","The representative COVID-19 cohort Munich (KoCo19): from the beginning of the pandemic to the Delta virus variant","Local","Journal Article (Peer-Reviewed)",NA,"Munich","""We randomly sampled the Munich cohort of private households between April 5th and June 12th, 2020. Only household members 14 years and older who gave written informed consent were included in the cohort. For participants younger than 18 years, informed consent was obtained from the parents as well as the par- ticipants themselves.""","""exclusion of children and residents not living in private households. ""","All","2020-04-05","2020-06-12","Household and community samples","Multiple groups",5313,0.016,0.011,0.021,"Simplified probability","Elecsys® Anti‐SARS‐CoV‐2 (N)","Roche Diagnostics","CLIA","IgG","Nucleocapsid(N-protein)","Validated by manufacturers",0.992,0.987,"https://dx.doi.org/10.1186/s12879-023-08435-1","No asymptomatics"
"Germany","Christin Heidemann","Long-term health consequences among individuals with SARS-CoV-2 infection compared to individuals without infection: results of the population-based cohort study CoMoLo Follow-up","Local","Journal Article (Peer-Reviewed)",NA,"Kupferzell, Bad Feilnbach, Straubing, Berlin-Mitte","The CoMoLo baseline study was a population-based study to investigate the seroprevalence of SARS-CoV-2 antibodies in four selected municipalities in Germany that were particularly affected by the COVID-19 pandemic in the year 2020 (i.e. with a reported cumulative SARS-CoV-2 incidence of more than 500 cases per 100,000 inhabitants before the start of the study). At baseline, random samples of adults (aged ≥ 18 years, n = 8999) from the local population registration offices were asked to visit a temporary study center to collect a blood sample and an oropharyngeal swab and to complete a short written questionnaire.","Fig 1:
- No valid consent for follow-up invitation (n=609)
- Deceased (n=18)
- No follow-up participation (n=2900)
- Missing IgG or PCR test at baseline study center (n=22)
- Missing self-report on laboratory-based physician diagnosis of COVID-19 at short baseline questionnaire (n=115)
- Missing self-report on laboratory test (n=16) or on physician diagnosis of COVID-19 at detailed baseline questionnaire (n=203)
- Missing self-report on PCR test at detailed follow-up questionnaire (n=35)
- First-time SARS-CoV-2 infection during follow-up based on self-report of positive PCR test at detailed follow-up questionnaire (n=264)","All","2020-05-15","2020-12-15","Household and community samples","Multiple groups",4817,0.06,NA,NA,"Simplified probability","Anti-SARS-CoV-2 QuantiVac ELISA","EUROIMMUN","ELISA","IgG","Spike",NA,NA,NA,"https://dx.doi.org/10.1186/s12889-023-16524-8","No representation"
"Ghana","Benedicta Ayiedu Mensah","Population-based sero-epidemiological investigation of the dynamics of SARS-CoV-2 infections in the Greater Accra Region of Ghana.","Local","Journal Article (Peer-Reviewed)",NA,"Accra","individual household members across 4 districts in Accra Ghana",NA,"All","2020-11-01","2020-11-30","Household and community samples","Multiple groups",1238,0.138,0.119,0.161,"Simplified probability","xMAP® SARS‑CoV‑2 Multi-Antigen IgG Assay","Luminex Corporation","Luminex","IgG","['Nucleocapsid(N-protein)', 'Spike']","Validated by manufacturers",1,0.997,"https://dx.doi.org/10.1038/s41598-022-25598-0","No representation"
"Greece","Ourania Tsitsilonis","Sars-cov-2 infection is asymptomatic in nearly half of adults with robust anti-spike protein receptor-binding domain antibody response","Local","Journal Article (Peer-Reviewed)","Attica","Athens","faculty members/laboratory assistants, scientific affiliates, administrative officers, undergraduate, and postgraduate students of NKUA",NA,"All","2020-06-15","2020-11-15","Multiple populations","Multiple groups",4996,0.016,0.0092,0.0254,"Simplified probability","Elecsys® Anti‐SARS‐CoV‐2 (N)","Roche Diagnostics","CLIA","['IgA', 'IgG', 'IgM']","Nucleocapsid(N-protein)","Validated by manufacturers",1,0.9981,"http://dx.doi.org/10.3390/vaccines9030207","No representation"
"Guinea","Abou Soumah","High and Rapid Increase in Seroprevalence for SARS-CoV-2 in Conakry, Guinea: Results From 3 Successive Cross-Sectional Surveys (ANRS COV16-ARIACOV).","Local","Journal Article (Peer-Reviewed)",NA,"Conakry","Gen pop of Conakry",NA,"All","2020-12-02","2020-12-26","Household and community samples","Multiple groups",535,0.173,0.124,0.238,"Stratified non-probability","xMAP® SARS‑CoV‑2 Multi-Antigen IgG Assay","Luminex Corporation","Luminex","IgG","['Nucleocapsid(N-protein)', 'Spike']","Validated by independent authors/third party/non-developers",NA,0.997,"https://dx.doi.org/10.1093/ofid/ofac152","Included"
"Ireland","Laura Heavey","The Study to Investigate COVID-19 Infection in People Living in Ireland (SCOPI): A seroprevalence study, June to July 2020.","Local","Journal Article (Peer-Reviewed)",NA,NA,"we selected random samples of people in each of two defined geographic areas, counties Dublin (population aged 12–69 years: n=1,021,801) and Sligo (population aged 12–69 years: n=47,718), which have high and low incidence of notified COVID-19 cases, respectively, which together represent 30% of the national population in this age group. Within age–sex strata, we selected participants using simple random sampling.","We excluded those 
under 12 years as phlebotomy is difficult in young children, and people aged 70 and older as they had been advised to stay at home during this study period.","All","2020-06-22","2020-07-16","Household and community samples","Multiple groups",913,0.0312,0.0205,0.0453,"Simplified probability","Abbott Architect SARS-CoV-2 IgG,Wantai SARS-CoV-2 Total Ab ELISA","Abbott Laboratories,Beijing Wantai Biological","Multiple Types","['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']","Multiple tests with diff validations or values derived from each type",NA,NA,"https://dx.doi.org/10.2807/1560-7917.ES.2021.26.48.2001741","Included"
"Israel","Aaron Rabinowitz","Antibody Tests  Show a Third in Israeli ultra-Orthodox Hot Spot Had Coronavirus","Local","News and Media",NA,"Bnei Brak","The municipality received a sample pool of names from the statistics bureau and its representatives called the people and persuaded them to take part in the survey.",NA,"All","2020-06-15","2020-08-15","Household and community samples","Multiple groups",3500,0.146,NA,NA,"Stratified probability","Not reported/ Unable to specify",NA,NA,NA,NA,NA,NA,NA,"https://www.haaretz.com/israel-news/.premium-antibody-tests-30-percent-of-bnei-brak-residents-have-been-infected-with-covid-1.9217689","News and media"
"Italy","Armando Di Landro","Bergamo serological tests, the results of Nembro and Alzano arrive: 61% positive","Local","News and Media","Lombardy","Alzano, Nembro",NA,NA,"All","2020-04-23","2020-04-28","Household and community samples","Multiple groups",750,0.61,NA,NA,"Unclear","Not reported/ Unable to specify",NA,NA,NA,NA,NA,NA,NA,"https://bergamo.corriere.it/notizie/cronaca/20_aprile_30/coronavirus-bergamo-primi-risultati-test-61percento-positivi-85e8e36c-8a6b-11ea-94d3-9879860c12b6.shtml?refresh_ce-cp","News and media"
"Italy","Alessandro  Baracco","SARS-CoV-2 Antibody Prevalence in Health Care Workers of Lodi Hospital, the COVID-19 Italian Epicentre","Local","Journal Article (Peer-Reviewed)","Lombardy region","Lodi","People belonging to the general population",NA,"All","2020-04-23","2020-05-05","Household and community samples","Multiple groups",1792,0.298,NA,NA,"Simplified probability","Liaison SARS-CoV-2 S1/S2 IgG","DiaSorin","CLIA","IgG","Spike",NA,NA,NA,"https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3650227","No representation"
"Italy","Pio Stellato","Successful management plan of COVID-19 in a pediatric hemato-oncology department: A single-centre experience","Local","Journal Article (Peer-Reviewed)","Campania","Naples","All paediatric patients and their caregivers from From 3 April until 29 May 2020 underwent rapid serological tests in the Hemato-Oncology Department of the Santobono-Pausilipon Hospital. All patients and their caregivers underwent rapid serological tests every 6 days in zone 1 (surveillance and screening zone of the department) before admission.
",NA,"All","2020-04-03","2020-05-29","Multiple populations","Multiple groups",1397,0.00429,NA,NA,"Convenience","VivaDiag COVID-19 IgM/IgG Rapid Test,Not reported/ Unable to specify","VivaChek Biotech (Hangzhou) Co. Ltd,NA","LFIA","['IgG', 'IgM']",NA,NA,NA,NA,"http://dx.doi.org/10.1136/bmjpo-2020-000818","No representation"
"Italy","Chiara Papalini","Seroprevalence of anti-SARS-CoV2 Antibodies in Umbrian Persons Living with HIV","Local","Journal Article (Peer-Reviewed)","Umbria","Perugia","HIV-seronegative individuals    tested    in    the    mentioned    period,",NA,"All","2020-05-04","2020-05-31","Multiple populations","Multiple groups",2843,0.054,NA,NA,"Unclear","Screen Test COVID-19 2019-nCOV IgG/IgM","Screen Italia S.R.L","LFIA","IgG",NA,"Validated by manufacturers",NA,NA,"https://dx.doi.org/10.4084/MJHID.2020.080","No representation"
"Italy","Francesa Cito","A COVID-19 Hotspot Area: Activities and Epidemiological Findings.","Local","Journal Article (Peer-Reviewed)","Abruzzo","Villa Caldari","persons officially registered as residents in Villa Caldari",NA,"All","2020-04-18","2020-04-19","Household and community samples","Multiple groups",667,0.109,0.088,0.135,"Entire sample","Wantai SARS-CoV-2 Total Ab ELISA","Beijing Wantai Biological","ELISA","TotalAntibody","Spike","Validated by independent authors/third party/non-developers",0.93,1,"https://dx.doi.org/10.3390/microorganisms8111711","Better study available"
"Italy","Daniela Alessi","[Seroprevalence of anti-SARS-CoV-2 IgG/IgM antibodies in Borgosesia (Piedmont Region, Northern Italy) population: a surveillance strategy in post-lockdown period?].","Local","Journal Article (Peer-Reviewed)","Piedmont","Borgosesia","Over the age of 18",NA,"All","2020-05-23","2020-05-24","Household and community samples","Multiple groups",4987,0.049,0.0433,0.0555,"Self-referral","PRIMA COVID-19 IgG/IgM Rapid Test","PRIMA Lab S.A.","LFIA","['IgG', 'IgM']",NA,"Validated by manufacturers",1,0.98,"https://dx.doi.org/10.19191/EP20.5-6.S2.119","No english"
"Italy","Antonio Bognanni","The Conundrum of Giglio Island: unraveling the dynamics of an apparent resistance to COVID-19. A descriptive study","Local","Preprint","Tuscany","Giglio Island","We invited the adult resident population, present on the island",NA,"All","2020-04-29","2020-05-03","Household and community samples","Adults (18-64 years)",723,0.00409999999999999,NA,NA,"Self-referral","COVID-19 IgG/IgM Rapid Test","Zhejiang Orient Gene Biotech","LFIA","['IgG', 'IgM']",NA,"Validated by manufacturers",0.879,1,"https://www.medrxiv.org/content/10.1101/2021.01.08.20248948v1","No representation"
"Italy","Pellegrino Cerino","Seroprevalence of SARS-CoV-2-specific antibodies in the town of Ariano Irpino (Avellino, Campania, Italy): a population-based study","Local","Journal Article (Peer-Reviewed)","Province of Avellino in the Campania region","Ariano Irpino","Screening was offered to all citizens inhabiting Ariano Irpino regardless of age but not to institutionalized citizens (e.g., those hospitalized or in prison). Only asymptomatic individuals and those who had not previously tested positive for SARS-CoV-2 on RT-PCR were included in the study",NA,"All","2020-05-16","2020-05-19","Household and community samples","Multiple groups",13218,0.056,0.052,0.06,"Convenience","Elecsys® Anti‐SARS‐CoV‐2 (N)","Roche Diagnostics","CLIA","TotalAntibody","Nucleocapsid(N-protein)",NA,NA,NA,"https://www.future-science.com/doi/10.2144/fsoa-2020-0203","No representation"
"Italy","Gabriele Pagani","Prevalence of SARS-CoV-2 in an area of unrestricted viral circulation: Mass seroepidemiological screening in Castiglione d'Adda, Italy","Local","Journal Article (Peer-Reviewed)","Lombardy","Castiglione D’Adda","Entire population of the town of Castiglione D'Adda","Did not consent to participate","All","2020-05-18","2020-06-07","Household and community samples","Multiple groups",4143,0.222,NA,NA,"Entire sample","PRIMA COVID-19 IgG/IgM Rapid Test","PRIMA Lab S.A.","LFIA","IgG",NA,"Validated by independent authors/third party/non-developers",1,0.96,"https://dx.doi.org/10.1371/journal.pone.0246513","Included"
"Italy","Roberto Melotti","Prevalence and determinants of serum antibodies to SARS-CoV-2 in the general population of the Gardena Valley","Local","Preprint",NA,"Gardena Valley ( Ortisei, Santa Cristina, and Selva, the main municipalities)","6+ years old,","Excluding pregnant women and <6 year old children, and excluding sampling from nursing homes.","All","2020-05-26","2020-06-08","Household and community samples","Multiple groups",2106,0.269,0.252,0.286,"Stratified probability","Abbott Architect SARS-CoV-2 IgG","Abbott Laboratories","CLIA","IgG","Nucleocapsid(N-protein)","Validated by independent authors/third party/non-developers",0.969,0.999,"10.1101/2021.03.19.21253883","Better study available"
"Italy","F Truc","The effects of physical distancing and lockdown to restrain SARS-CoV-2 outbreak in the Italian Municipality of Cogne","Local","Preprint","Valle D'Aosta","Cogne","people living to Cogne down town and spending there a considerable fraction of their time","Children under 14 years old were excluded from the survey.","All","2020-06-04","2020-06-05","Household and community samples","Multiple groups",857,0.0338,NA,NA,"Entire sample","iFlash-SARS-CoV-2 IgM/IgG","Shenzhen Yhlo Biotech Co. Ltd","CLIA","['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']","Validated by manufacturers",NA,NA,"https://www.medrxiv.org/content/10.1101/2021.03.19.21253962v1.full-text","No representation"
"Italy","Ilaria Dorigatti","SARS-CoV-2 antibody dynamics and transmission from community-wide serological testing in the Italian municipality of Vo'.","Local","Journal Article (Peer-Reviewed)","Padova","Vo","Population of Vo'","Excluding indeterminant assay results","All","2020-05-01","2020-05-31","Household and community samples","Multiple groups",2602,0.035,0.028,0.043,"Entire sample","Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N),Liaison SARS-CoV-2 S1/S2 IgG","Abbott Laboratories,Roche Diagnostics,DiaSorin","CLIA","IgG","['Nucleocapsid(N-protein)', 'Spike']","Validated by independent authors/third party/non-developers",NA,NA,"https://dx.doi.org/10.1038/s41467-021-24622-7","No asymptomatics"
"Italy","Nausicaa Berselli","Seroprevalence of anti-SARS-CoV-2 antibodies in the Northern Italy population before the COVID-19 second wave.","Local","Journal Article (Peer-Reviewed)","Province of Modena","Modena","Workers and individuals who went to the private Test Laboratory of Modena Workers for a serological test between June 1-September 25, 2020. Workers were referred by their companies, which strongly recommended that their employees be tested. The remaining individuals were admitted to the facility through self-referral, and were not asked to report the reasons for which they sought testing.","For subjects who took the test more than once during the study period, only their most recent test result was considered and the previous ones were excluded from the analysis.","All","2020-06-01","2020-09-25","Multiple populations","Multiple groups",7561,0.047,0.042,0.052,"Self-referral","Elecsys® Anti‐SARS‐CoV‐2 (N),Diagnostic kit for SARS-CoV-2 IgM/IgG Antibody (Colloidal Gold),Anti-SARS-CoV-2 ELISA IgA,Anti-SARS-CoV-2 ELISA IgG","Roche Diagnostics,Shanghai Kehua Bio-engineering (KHB) Co. Ltd,EUROIMMUN","Multiple Types","['IgA', 'IgG', 'IgM']",NA,"Validated by manufacturers",NA,NA,"https://dx.doi.org/10.13075/ijomeh.1896.01826","No representation"
"Italy","Carmine Coppola","Associated screening for HCV and SARS-Cov2 infection in an urban area of Southern Italy: a cohort study.","Local","Journal Article (Peer-Reviewed)","Naples","City of Napoli",NA,"Aged <6 years and resident abroad at the time.","All","2020-06-25","2020-07-12","Household and community samples","Multiple groups",2738,0.014,NA,NA,"Self-referral","VivaDiag COVID-19 IgM/IgG Rapid Test","VivaChek Biotech (Hangzhou) Co. Ltd","LFIA","['IgG', 'IgM']",NA,NA,NA,NA,"https://dx.doi.org/10.1111/jvh.13623","No representation"
"Italy","Marco Bassanello","Epidemiological study in a small rural area of Veneto (Italian region) during Sars-Cov-2 Pandemia.","Local","Journal Article (Peer-Reviewed)","Veneto",NA,"The study involved one subject per family within a population of about 4400 people in the town of Monastier di Treviso (Veneto Region, Italy). This has approximately 1750 families, with an average of 2.49 subjects per family (source: Municipality of Monastier di Treviso). A total of 922 people was recruited (about a quarter of the area’s population). Recruitment was random and families remained free to participate; generally, the ones most
at risk and the ones who had certainly been infected participated.",NA,"All","2020-05-04","2020-07-15","Household and community samples","Multiple groups",922,0.021,NA,NA,"Stratified probability","Not reported/ Unable to specify",NA,"Other","IgG",NA,NA,NA,NA,"https://dx.doi.org/10.1038/s41598-021-02654-9","No representation"
"Italy","Valentina Pecoraro","Big Data analysis to evaluate the clinical utility of IgM anti SARS-CoV-2 determination: The Modena experience","Local","Journal Article (Peer-Reviewed)","Modena","Modena","data already present in the database of the USL of Modena were analyzed; subjects with positive results were subsequently contacted by the Department of Hygiene and Public Health for the execution of an oral- or nasopharyngeal swab for the search for viral RNA for definitive diagnosis",NA,"All","2020-03-11","2020-09-30","Multiple populations","Multiple groups",533,0.159,NA,NA,"Convenience","iFlash-SARS-CoV-2 IgM/IgG,Rapid Test SARS-CoV-2 IgM/IgG Gold","Shenzhen Yhlo Biotech Co. Ltd,Technogenetics","Multiple Types","['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",NA,NA,NA,"https://dx.doi.org/10.19186/BC_2022.014","No asymptomatics"
"Italy","Zeno Bisoffi","Two-Year Cohort Study of SARS-CoV-2, Verona, Italy, 2020-2022","Local","Journal Article (Peer-Reviewed)","Veneto","Verona",">10 years of age lived in Verona",NA,"All","2020-04-25","2020-05-08","Household and community samples","Multiple groups",1515,0.027,NA,NA,"Simplified probability","Abbott Architect SARS-CoV-2 IgG","Abbott Laboratories","CLIA","IgG","Nucleocapsid(N-protein)",NA,NA,NA,"https://dx.doi.org/10.3201/eid2904.221268","No asymptomatics"
"Japan","Simon Denyer","Japanese firm's blanket testing of employees  could serve as model","Local","News and Media",NA,NA,"family members, clients, employees of SoftBank, or medical workers",NA,"All","2020-05-12","2020-05-18","Multiple populations","Multiple groups",38216,0.0023,NA,NA,"Convenience","Not reported/ Unable to specify",NA,NA,NA,NA,NA,NA,NA,"https://www.google.com/url?rct=j&sa=t&url=https://www.lmtonline.com/news/article/Japanese-firm-s-blanket-testing-of-employees-15355433.php&ct=ga&cd=CAEYHCoUMTM4NjAwODY3NjE3NzkyOTU2ODYyGjkwZGVhOTg5OTRlOTE4NTk6Y29tOmVuOlVT&usg=AFQjCNGl9_tc35Q3fUbB67SoWaNsH2ltMw","News and media"
"Japan","Melissa M Matthews","COVID-19 serological survey using micro blood sampling.","Local","Journal Article (Peer-Reviewed)","Okinawa Prefecture","Okinawa","Students and employees of the Okinawa Insitute of Science and Technology",NA,"All","2020-08-01","2020-08-31","Multiple populations","Adults (18-64 years)",675,0,NA,NA,"Convenience","Author designed (ELISA) -Spike",NA,"ELISA",NA,"Spike","Validated by independent authors/third party/non-developers",0.925,1,"https://dx.doi.org/10.1038/s41598-021-88850-z","No representation"
"Japan","Kenji Mizumoto","SARS-CoV-2 IgG seroprevalence in the Okinawa Main Island and remote islands in Okinawa, Japan, 2020-2021","Local","Journal Article (Peer-Reviewed)","Okinawa Prefecture",NA,"All patients who visited and underwent blood collection for any reason at the emergency departments during these periods were included in this study unless they explicitly chose to be excluded","All patients who visited and underwent blood collection for any reason at the emergency departments during these periods were included in this study unless they explicitly chose to be excluded","All","2020-10-01","2020-12-31","Household and community samples","Multiple groups",1448,0.006,0.002,0.011,"Convenience","Author designed (ELISA) -Spike",NA,"ELISA","IgG","Spike","Validated by independent authors/third party/non-developers",0.925,1,"https://www.medrxiv.org/content/10.1101/2022.03.02.22271759v1.full-text","No representation"
"Japan","Aya Sugiyama","A longitudinal study of anti-SARS-CoV-2 antibody seroprevalence in a random sample of the general population in Hiroshima in 2020.","Local","Journal Article (Peer-Reviewed)","Chūgoku Region","Hiroshima, Fukuyama, Higashi-Hiroshima, Miyoshi, and Kita-Hiroshima","Individuals were included based on the Basic Resident Register","Only adults over the age of 20 were included","All","2020-08-01","2020-09-30","Household and community samples","Multiple groups",3025,3e-04,0,0.001,"Stratified probability","VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG,VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total,Abbott Architect SARS-CoV-2 IgG,cPass SARS-CoV-2 Surrogate Virus Neutralization Test ELISA Kit,Qualitative Elecsys Anti-SARS-CoV-2 Probe","Ortho Clinical Diagnostics Inc.,Abbott Laboratories,GenScript,Roche Diagnostics","Multiple Types","['IgG', 'TotalAntibody']","['Nucleocapsid(N-protein)', 'Spike']","Validated by manufacturers",NA,NA,"https://dx.doi.org/10.1265/ehpm.22-00016","No representation"
"Kenya","Patrick Munywoki","Seroprevalence and risk factors of SARS-CoV-2 infection in an urban informal settlement in Nairobi","Local","Journal Article (Peer-Reviewed)","Nairobi",NA,"All residents of the Kibera settlement in Nairobi, Kenya.  ""all household members, both adults and children, regardless of current or prior COVID-19 infection status.""",NA,"All","2020-11-27","2020-12-05","Household and community samples","Multiple groups",511,0.433,0.374,0.495,"Simplified probability","Wantai SARS-CoV-2 Total Ab ELISA","Beijing Wantai Biological","ELISA","['IgG', 'IgM']","Spike","Validated by manufacturers",0.944,1,"https://f1000research.com/articles/10-853","No representation"
"Kenya","Isaac Ngere","High seroprevalence of SARS-CoV-2 but low infection fatality ratio eight months after introduction in Nairobi, Kenya","Local","Journal Article (Peer-Reviewed)",NA,NA,"Consenting residents in selected households (irrespective of age) who had lived in the city for at least six months preceding the survey were enrolled","Persons with reported or documented contraindications to venipuncture were excluded.","All","2020-11-02","2020-11-23","Household and community samples","Multiple groups",1164,0.347,0.318,0.376,"Simplified probability","Wantai SARS-CoV-2 Total Ab ELISA","Beijing Wantai Biological","ELISA","['IgG', 'IgM']",NA,"Validated by manufacturers",0.944,1,"https://dx.doi.org/10.1016/j.ijid.2021.08.062","Included"
"Libya","Amal A Elfakhri","Population-Based Random Survey for detection of COVID-19 Infection and Seroprevalence in Benghazi- Libya May/2020","Local","Journal Article (Peer-Reviewed)",NA,"Benghazi","individuals in Benghazi, including all geographical areas of Benghazi and all persons irrespective of their age, gender or nationality.",NA,"All","2020-05-02","2020-05-07","Household and community samples","Multiple groups",600,0,NA,NA,"Stratified probability","Not reported/ Unable to specify",NA,"LFIA","['IgG', 'IgM']",NA,"Validated by manufacturers",0.817,0.967,"https://preventive-medicine.imedpub.com/populationbased-random-survey-for-detection-of-covid19-infection-and-seroprevalence-in-benghazi-libya-may2020.pdf","No asymptomatics"
"Malawi","C Meinus","SARS-CoV-2 prevalence and immunity: a hospital-based study from Malawi.","Local","Journal Article (Peer-Reviewed)","Central Region","Lilongwe","The study population included participants working or presenting at the facility. HCWs were defined as health care professionals, allied health workers and administration; non-HCWs were defined as patients, guardians, and relatives. Participants were selected through convenience sampling, aiming at an equal distribution of HCWs and non-HCWs.","Participants under 18 years and those who presented with contraindications to venipuncture or unwilling or unable to consent were excluded.","All","2020-08-24","2020-09-03","Multiple populations","Multiple groups",914,0.0799,NA,NA,"Convenience","Anti-SARS-CoV-2 ELISA IgG,cPass SARS-CoV-2 Surrogate Virus Neutralization Test ELISA Kit","EUROIMMUN,GenScript","ELISA","['IgG', 'Neutralizing']","Spike","Multiple tests with diff validations or values derived from each type",NA,NA,"https://dx.doi.org/10.1016/j.ijid.2021.12.336","No representation"
"Maldives","Raheema Abdul-Raheem","A sero-epidemiological study after two waves of the COVID-19 epidemic.","Local","Journal Article (Peer-Reviewed)",NA,"Male'","The study population were the people living in Male’ at the time of survey.",NA,"All","2020-10-15","2020-11-16","Household and community samples","Multiple groups",1940,0.134,NA,NA,"Stratified probability","VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total","Ortho Clinical Diagnostics Inc.","CLIA","TotalAntibody","Spike","Validated by independent authors/third party/non-developers",0.9,1,"https://apjai-journal.org/wp-content/uploads/2022/01/AP-040721-1177.pdf","Included"
"Mali","Issaka Sagara","Rapidly Increasing Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence and Limited Clinical Disease in 3 Malian Communities: A Prospective Cohort Study","Local","Journal Article (Peer-Reviewed)","Bamako","Bamako","We assessed individuals aged 6 months or older from 3 communities in Mali for anti-SARS-CoV-2 antibodies.

...

Community members including those enrolled in existing malaria studies were invited to participate.",NA,"All","2020-07-29","2020-10-16","Household and community samples","Multiple groups",587,0.19,0.142,0.238,"Convenience","Author designed (ELISA) -Spike",NA,"ELISA","IgG","Spike","Validated by independent authors/third party/non-developers",0.739,0.994,"https://doi.org/10.1093/cid/ciab589","No representation"
"Mali","Dagmar Alber","SARS-CoV-2 infection and antibody seroprevalence in routine surveillance patients, healthcare workers and general population in Kita region, Mali: an observational study 2020–2021","Local","Journal Article (Peer-Reviewed)",NA,"Kita","apparently healthy community residents in 16 villages in or near Kita town, Mali",NA,"All","2020-12-01","2020-12-31","Household and community samples","Multiple groups",875,0.2766,NA,NA,"Stratified probability","Wantai SARS-CoV-2 Total Ab ELISA","Beijing Wantai Biological","ELISA","['IgG', 'IgM']","Spike","Validated by manufacturers",0.93,1,"https://dx.doi.org/10.1136/bmjopen-2021-060367","No representation"
"Mali","Mady Cissoko","SARS-CoV-2 seroprevalence and living conditions in Bamako (Mali): a cross-sectional multistage household survey after the first epidemic wave, 2020","Local","Journal Article (Peer-Reviewed)",NA,"Bamako","After selecting houses in Bamako, Mali, with a multi-stage cluster sampling method, ""all household members in the age range willing to participate were recruited. The study was conducted among the general population aged ≥1 year old for the seroprevalence study, and ≥12 years old for the questionnaire survey.""","Individuals with missing IgG results were excluded from the seroprevalence analysis [but not IgM].

Out of 1526 participants, 2 did not provide samples, 170 had no interpretable test results for both IgG and IgM, and 27 inconclusive results due to a missing IgG and negative IgM results or inversely.","All","2020-09-01","2020-09-30","Household and community samples","Multiple groups",1327,0.164,0.08,0.249,"Stratified probability","VIDAS® SARS-COV-2 IgG,VIDAS® SARS-COV-2 IgM","BioMérieux","ELISA,ELISA","['IgG', 'IgM']","Spike","Validated by manufacturers",NA,NA,"https://dx.doi.org/10.1136/bmjopen-2022-067124","No asymptomatics"
"Mozambique","Eduardo Samo Gudo","Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Nampula","Local","Presentation or Conference","Nampula","Nampula",NA,NA,"All","2020-06-17","2020-06-30","Household and community samples","Multiple groups",1769,0.05,0.04,0.06,"Stratified probability","Standard Q COVID-19 IgM/IgG Duo rapid immunochromatography test kit","SD Biosensor","LFIA","['IgG', 'IgM']",NA,NA,NA,NA,"https://covid19.ins.gov.mz/wp-content/uploads/2020/12/Inquerito-SARS-CoV-2-NAMPULA_vfinal.pdf","Conference article"
"Mozambique","Paulo Arnaldo","Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Pemba (InCOVID 2020)","Local","Presentation or Conference","Cabo Delgado","Pemba",NA,NA,"All","2020-07-06","2020-07-13","Household and community samples","Multiple groups",1360,0.025,NA,NA,"Stratified probability","Hightop COVID-19 IgM/IgG Ab Rapid Test Kit","Qingdao Hightop Biotech Co. Ltd","LFIA","['IgG', 'IgM']",NA,NA,NA,NA,"https://covid19.ins.gov.mz/wp-content/uploads/2020/09/Inquerito-SARS-CoV-2-PEMBA_-RESULTADOS-PRELIMINARES_FINAL_3_27.07.2020.pdf","Conference article"
"Mozambique","Edna Viegas","Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Maputo (InCOVID 2020)","Local","Presentation or Conference",NA,"Maputo",NA,NA,"All","2020-08-03","2020-08-21","Household and community samples","Multiple groups",4717,0.0379,NA,NA,"Stratified probability","Panbio COVID-19 IgG/IgM rapid test device","Abbott Laboratories","LFIA","['IgG', 'IgM']",NA,NA,NA,NA,"https://covid19.ins.gov.mz/wp-content/uploads/2020/08/Inqu%C3%A9rito-SE-SARS-CoV-2_Cidade-de-Maputo_resultados_31Ago2020.pdf","Conference article"
"Mozambique","Mussagy Mahomed","Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Tete (InCOVID 2020)","Local","Presentation or Conference","Tete","Tete",NA,NA,"All","2020-08-31","2020-10-12","Household and community samples","Multiple groups",1946,0.00699999999999999,NA,NA,"Stratified probability","Hightop COVID-19 IgM/IgG Ab Rapid Test Kit","Qingdao Hightop Biotech Co. Ltd","LFIA","['IgG', 'IgM']",NA,NA,NA,NA,"https://covid19.ins.gov.mz/wp-content/uploads/2020/09/Inque%CC%81rito-SE-SARS-CoV-2_Cidade-de-Tete_resultados.pdf","Conference article"
"Mozambique","Nedio Mabunda","Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Beira (InCOVID 2020)","Local","Presentation or Conference","Sofala","Beira",NA,NA,"All","2020-09-21","2020-10-02","Household and community samples","Multiple groups",4940,0.052,NA,NA,"Stratified probability","Panbio COVID-19 IgG/IgM rapid test device","Abbott Laboratories","LFIA","['IgG', 'IgM']","Nucleocapsid(N-protein)",NA,NA,NA,"https://covid19.ins.gov.mz/wp-content/uploads/2020/10/InCOVID-2020_-BEIRA_-RESULTADOS-PRELIMINARES.pdf","Conference article"
"Mozambique","Jeronimo Langa","Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Lichinga (InCOVID 2020)","Local","Presentation or Conference","Niassa","Lichinga",NA,NA,"All","2020-09-28","2020-10-09","Household and community samples","Multiple groups",1635,0.003,NA,NA,"Stratified probability","Hightop COVID-19 IgM/IgG Ab Rapid Test Kit","Qingdao Hightop Biotech Co. Ltd","LFIA","['IgG', 'IgM']",NA,NA,NA,NA,"https://covid19.ins.gov.mz/wp-content/uploads/2020/10/Inquerito-SE-SARS-CoV-2-Lichinga_19-10-020.pdf","Conference article"
"Mozambique","Ivalda Macicame","Inquérito Sero-epidemiológico de SARS-CoV-2 na Província de Maputo (InCOVID 2020)","Local","Presentation or Conference","Maputo","Matolo",NA,NA,"All","2020-09-14","2020-09-30","Household and community samples","Multiple groups",5394,0.0356,NA,NA,"Stratified probability","Panbio COVID-19 IgG/IgM rapid test device","Abbott Laboratories","LFIA","['IgG', 'IgM']",NA,NA,NA,NA,"https://covid19.ins.gov.mz/wp-content/uploads/2020/10/Inque%CC%81rito-Provincia-de-Maputo_resultados-preliminares_21Out2020-versao-final.pdf","Conference article"
"Mozambique","Arlete Mahumane","Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Chimoio (InCOVID 2020)","Local","Presentation or Conference","Manica Province","Chimoio",NA,NA,"All","2020-11-02","2020-11-17","Household and community samples","Multiple groups",9756,0.014,NA,NA,"Stratified probability","Hightop COVID-19 IgM/IgG Ab Rapid Test Kit","Qingdao Hightop Biotech Co. Ltd","LFIA","['IgG', 'IgM']",NA,NA,NA,NA,"https://covid19.ins.gov.mz/wp-content/uploads/2020/11/Inqueirito-SE-SARS-CoV-2-de-Cidade-de-Chimoio-Resultados-preliminares-27-Nov-2020-V_1.1_corrigido-I_JANI_FINAL1.pdf","Conference article"
"Mozambique","Paulo Arnaldo","Inquérito Sero-epidemiológico de SARS-CoV-2 nas Cidades de Xai-Xai e Chókwè (InCOVID 2020)","Local","Presentation or Conference","Gaza","Chokwe",NA,NA,"All","2020-11-16","2020-11-21","Household and community samples","Multiple groups",2451,0.053,NA,NA,"Stratified probability","Panbio COVID-19 IgG/IgM rapid test device","Abbott Laboratories","LFIA","['IgG', 'IgM']",NA,NA,NA,NA,"https://covid19.ins.gov.mz/wp-content/uploads/2020/12/InCOVID-2020_-XAI-XAI-CHOKWE_-RESULTADOS-PRELIMINARES_08-12-2020.pdf","Conference article"
"Mozambique","Mussagy Mahomed","Inquérito Sero-epidemiológico de SARS-CoV-2 na Cidade de Maxixe e Vila de Massinga (InCOVID 2020)","Local","Presentation or Conference","Inhambane","Massinga",NA,NA,"All","2020-11-26","2020-12-03","Household and community samples","Multiple groups",1577,0.074,NA,NA,"Stratified probability","Hightop COVID-19 IgM/IgG Ab Rapid Test Kit","Qingdao Hightop Biotech Co. Ltd","LFIA","['IgG', 'IgM']",NA,NA,NA,NA,"https://covid19.ins.gov.mz/wp-content/uploads/2020/12/Inquerito-de-SARS-CoV-2_Maxixe-e-Massinga.pdf","Conference article"
"Mozambique","Paulo Arnaldo","Prevalence of SARS-CoV-2 antibodies in the Mozambican population: a cross-sectional Serologic study in three cities, July-August 2020","Local","Journal Article (Peer-Reviewed)","Maputo","Maputo City",NA,"""If participants refused to provide consent for the interview or blood collection, they were excluded.""","All","2020-08-04","2020-08-24","Household and community samples","Multiple groups",4719,0.021,0.012,0.033,"Stratified probability","Panbio COVID-19 IgG/IgM rapid test device","Abbott Laboratories","LFIA","['IgG', 'IgM']","Spike","Validated by independent authors/third party/non-developers",0.833,0.98,"https://dx.doi.org/10.1093/cid/ciac516","No representation"
"Nicaragua","Hannah E. Maier","Clinical spectrum of SARS-CoV-2 infection and protection from symptomatic re-infection","Local","Journal Article (Peer-Reviewed)",NA,"Managua","The Household Influenza Cohort Study (HICS) began in 2017
and is an ongoing study in Managua, Nicaragua. HICS is a
community-based cohort in which participants are provided
with their primary care, are encouraged to report to the study
health center at the first indication of any illness, and are followed
for influenza infection and illness. 

Annual blood samples were collected in March 2020 or at enrollment, and midyear samples were collected during October–November 2020.",NA,"All","2020-10-15","2020-11-15","Household and community samples","Multiple groups",1995,0.575,NA,NA,"Self-referral","Author designed (ELISA) -Spike",NA,"ELISA","IgG","Spike",NA,NA,NA,"http://dx.doi.org/10.1093/cid/ciab717","No representation"
"Nicaragua","Fredman Gonzalez","Seroepidemiology of SARS-CoV-2 infections in an urban population-based cohort in Leon, Nicaragua","Local","Journal Article (Peer-Reviewed)",NA,"León","Participants of The Sapovirus-Associated Gastro-Enteritis (SAGE) study, a population-based birth cohort
study in León, Nicaragua. ""Starting in July 2020, we contacted the household members of
350 cohort children (both adults and children) and offered participation in this study. We also offered participation in the study for
cohort children, including those who had reached 36 months of
age. Any interested household members were eligible to enrol,
and not all household members were required to enrol.""",NA,"All","2020-09-15","2020-10-15","Household and community samples","Multiple groups",1243,0.268,0.233,0.301,"Convenience","Author designed (ELISA) -Spike",NA,"ELISA","TotalAntibody","Spike","Validated by independent authors/third party/non-developers",0.952,0.967,"10.1017/s0950268821002144","No representation"
"Pakistan","Faiza Rezwan","is karachi knocking at herd immunity? a possible reason for decline in sars-cov-2 infections","Local","Preprint","Sindh","Kararchi","The study included adult male and female participants from different segments of the population.","RT-PCR proven COVID-19 cases were excluded","All","2020-08-30","2020-09-12","Household and community samples","Adults (18-64 years)",2404,0.55,NA,NA,"Convenience","Not reported/ Unable to specify",NA,"CLIA","['IgA', 'IgG', 'IgM']","Nucleocapsid(N-protein)","Validated by manufacturers",NA,NA,"https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3700931","No representation"
"Pakistan","Muhammed Imran Nisar","Serial population-based serosurveys for COVID-19 in two neighbourhoods of Karachi, Pakistan","Local","Journal Article (Peer-Reviewed)","Karachi","District East","all household members were eligible to participate regardless of their infectious status","Facilities such as hospitals, care homes, educational institutions and prison were excluded. However, healthcare workers within a household were not excluded.","All","2020-04-15","2020-04-25","Household and community samples","Multiple groups",500,0.004,0,0.013,"Simplified probability","Elecsys® Anti‐SARS‐CoV‐2 (N)","Roche Diagnostics","CLIA","['IgG', 'IgM']",NA,"Validated by manufacturers",1,0.998,"http://dx.doi.org/10.1016/j.ijid.2021.03.040","Included"
"Pakistan","Mirza Amir Baig","Prevalence of SARS-CoV-2: An age-stratified, population-based, seroepidemiological survey in Islamabad, Pakistan","Local","Preprint","Islamabad Capital Territory","Islamabad","Residents of households in both urban and rural administrative units of the district of Islamabad, Pakistan. A household was defined as “a dwelling with a 140 common kitchen or common opening onto a shared space.” All persons living in a household were included in the study for representation of all ages and genders.",NA,"All","2020-06-01","2020-06-30","Household and community samples","Multiple groups",6333,0.163,NA,NA,"Stratified probability","Panbio COVID-19 IgG/IgM rapid test device","Abbott Laboratories","CLIA","['IgG', 'IgM']",NA,NA,NA,NA,"https://www.medrxiv.org/content/10.1101/2021.09.27.21264003v1.article-info","Preprint"
"Paraguay",NA,"30% of those tested in the East had Covid","Local","News and Media",NA,"Ciudad del Este","Households in Ciudad del Este,",NA,"All","2020-11-29","2020-12-15","Household and community samples","Multiple groups",1675,0.3,NA,NA,"Unclear","Not reported/ Unable to specify",NA,NA,NA,NA,NA,NA,NA,"https://www.ultimahora.com/el-30-testeados-el-este-tuvieron-covid-n2918654.html","News and media"
"Paraguay","Agueda Cabello","High Circulation of SARS-CoV-2 In Ciudad del Este District, Paraguay, 2020","Local","Journal Article (Peer-Reviewed)","Alto Paraná department","Ciudad del Este","Residents of the Ciudad del Este district of Alto Paraná department in Paraguay.",NA,"All","2020-10-27","2020-11-21","Household and community samples","Multiple groups",1978,0.2988,NA,NA,"Simplified probability","COVID-19 IgG/IgM Rapid Test","Zhejiang Orient Gene Biotech","LFIA","['IgG', 'IgM']","Spike","Validated by independent authors/third party/non-developers",0.84,0.87,"https://revsaludpublica.sld.cu/index.php/spu/article/view/3850","No english"
"Poland","Dagny Lorent","Prevalence of anti-SARS-CoV-2 antibodies in Poznan Poland, after the first wave of the COVID-19 pandemic","Local","Preprint","Greater Poland","Poznań","We randomly selected and invited 1500 adult (over 18 years old) study participants from approximately 15,000 volunteers living in the Poznań metropolitan area",NA,"All","2020-07-15","2020-09-15","Household and community samples","Multiple groups",1500,0.0093,0.0056,0.0156,"Simplified probability","Anti-SARS-CoV-2 ELISA IgG,anti-SARS-CoV-2 IgG immunoblot","EUROIMMUN,Polycheck","Multiple Types","IgG","['Nucleocapsid(N-protein)', 'Spike']",NA,NA,NA,"https://www.medrxiv.org/content/10.1101/2021.03.29.21254544v1.full","No representation"
"Poland","Jan Zejda","[Infection Fatality Rate (IFR) during the course of COVID-19 pandemic in Upper Silesia Metropolitan Area (Poland) in 2020].","Local","Journal Article (Peer-Reviewed)",NA,"Katowice, Gliwice and Sosnowiec","A group of 6,000 people was drawn. inhabitants of 3 cities (Katowice, Gliwice and Sosnowiec) including all age groups (1-94)",NA,"All","2020-10-15","2020-11-15","Household and community samples","Multiple groups",1167,0.114,0.095,0.132,"Simplified probability","Anti-SARS-CoV-2 ELISA IgG","EUROIMMUN","ELISA","IgG",NA,"Validated by manufacturers",0.88,0.99,"https://dx.doi.org/10.13075/mp.5893.01179","No english"
"Romania","Corina Manolea","Serological Testing for COVID-19 in the Fertility Setting: The Lockdown Impact and Subsequent Dynamics Reflected in the Seroprevalence of Sars-Cov-2 Antibodies","Local","Preprint",NA,"Bucharest","Triage negative (pt or partner asymptomatic)","Triage positive (pt or partner)","All","2020-05-17","2020-12-01","Multiple populations","Adults (18-64 years)",546,0.06,NA,NA,"Convenience","Liaison SARS-CoV-2 S1/S2 IgG","DiaSorin","CLIA","['IgG', 'IgM']","Spike","Validated by manufacturers",0.907,0.986,"https://www.preprints.org/manuscript/202101.0024/v1","No representation"
"Russian Federation","Jonny Tickle","Large-scale antibody testing reveals that over 2 million Muscovites may already have contracted ...","Local","News and Media","Central Russia","Moscow","Resident of Moscow",NA,"All","2020-06-05","2020-06-18","Household and community samples","Multiple groups",90000,0.199,NA,NA,"Simplified probability","Not reported/ Unable to specify",NA,NA,NA,NA,NA,NA,NA,"https://www.google.com/url?rct=j&sa=t&url=https://www.rt.com/russia/493055-moscow-mass-antibody-testing/&ct=ga&cd=CAEYESoUMTExMTExNDMxMTUyMzY3OTYzMDcyGjkwZGVhOTg5OTRlOTE4NTk6Y29tOmVuOlVT&usg=AFQjCNHh2eLjbkaY212mSAjMBempJCE7bA","News and media"
"Russian Federation","Anna Popova","Herd Immunity to SARS-CoV-2 among the Population in Saint-Petersburg during the COVID-19 Epidemic","Local","Journal Article (Peer-Reviewed)",NA,"Saint-Petersburg",NA,"The exclusion criterion was active COVID-19 infection at the time of the survey.","All","2020-06-15","2020-06-20","Household and community samples","Multiple groups",2713,0.26,0.243,0.277,"Simplified probability","Author designed (ELISA) - Nucleocapsid",NA,"ELISA","IgG","Nucleocapsid(N-protein)",NA,NA,NA,"https://journal.microbe.ru/jour/article/view/1372/1151","No english"
"Russian Federation","Popova A Yu","Collective immunity to SARS-COV-2 of moscow residents during the COVID-19 epidemic period","Local","Journal Article (Peer-Reviewed)",NA,"Moscow",NA,"The exclusion criterion was active infection,
COVID-19 at the time of the survey","All","2020-07-01","2020-07-30","Household and community samples","Multiple groups",2688,0.221,NA,NA,"Simplified probability","ELISA anti-SARS-CoV reagent kit -2 IgG","FBSI State scientific center for applied microbiology and biotechnology","ELISA","IgG","Nucleocapsid(N-protein)",NA,NA,NA,"http://dx.doi.org/10.20953/1729-9225-2020-4-8-16","No english"
"Russian Federation","Anna Popova","Herd immunity to SARS-CoV-2 in the Novosibirsk Region population amid the COVID-19 pandemic","Local","Journal Article (Peer-Reviewed)",NA,"Kochenyevsky, Krasnozyersky, Moshkovsky, Novosibirsk, Elitny Village, Toguchinsky Districts","The selection of volunteers was carried out using the anke-using cloud technologiesand randomization by age and areaprinciples.","The exclusion criterion was the presencemanifest form of COVID-19 at the time of the questionnairevania","All","2020-06-28","2020-07-15","Household and community samples","Multiple groups",2728,0.091,0.08,0.102,"Stratified probability","ELISA anti-SARS-CoV reagent kit -2 IgG","FBSI State scientific center for applied microbiology and biotechnology","ELISA","IgG","Nucleocapsid(N-protein)",NA,NA,NA,"https://dx.doi.org/10.36233/0507-4088-54","No english"
"Russian Federation","Vladimir Gorodin","Dynamics of seroprevalence of anti-SARS-CoV-2 antibodies in non-vaccinated people","Local","Journal Article (Peer-Reviewed)","Krasnodar Kai","Krasnodar","Study was carried out at the CL laboratory in Krasnodar in a group of 806 unvaccinated people working in a relatively isolated team. Each subject was characterized by a negative PCR test for SARS-CoV-2 and the absence of clinical signs of COVID-19 at the time of blood serum sampling and in the previous
three months before that.",NA,"All","2020-10-26","2020-12-30","Household and community samples","Adults (18-64 years)",806,0.132,NA,NA,"Convenience","Access SARS-CoV-2 IgG Reagent Antibody Test","Beckman Coulter","Neutralization","IgG","Spike",NA,NA,NA,"https://dx.doi.org/10.20953/1729-9225-2021-4-98-102","No english"
"Russian Federation","Viacheslav Smirnov","Longitudinal Randomized Cohort Study of SARS-CoV-2 Antibody Seroprevalence in the St. Petersburg Population","Local","Preprint","Saint Petersburg","Saint Petersburg","Sampled from a previous cross-sectional study of 2713 volunteers in St. Petersburg. Had to have participated in all 5 stages of seromonitoring.",NA,"All","2020-06-15","2020-06-20","Household and community samples","Multiple groups",1000,0.038,0.028,0.05,"Simplified probability","Author designed (ELISA) -Spike",NA,"ELISA","IgG","Spike",NA,NA,NA,"10.20944/preprints202204.0165.v1","Preprint"
"Russian Federation","Ekaterina V Parshina","Prevalence and Dynamics of SARS-CoV-2 Antibodies in the Population of St. Petersburg, Russia.","Local","Journal Article (Peer-Reviewed)","Northwestern Federal District","St. Petersburg","The dataset was based on systematized information obtained from 
the Saint Petersburg State University Hospital laboratory 
database, inclusively summarizing the demographic factors, etiological categories of patients, results of SARSCoV-2 detection by real-time PCR, and serum IgA, IgM, 
and IgG antibodies for SARS-CoV-2, performed from May 
to November 2020.",NA,"All","2020-05-15","2020-11-15","Household and community samples","Multiple groups",158283,0.167,NA,NA,"Sequential","Anti-SARS-CoV-2 ELISA IgA,Architect Anti-SARS-CoV-2 IgM,SARS- CoV-2-IgG-EIA-BEST and SARS-CoV-2- IgM-EIA-BEST ,Author designed (ELISA) -Unknown,Not reported/ Unable to specify","EUROIMMUN,Abbott Laboratories,Vector BEST,NA","Multiple Types","['IgA', 'IgG', 'IgM']",NA,NA,NA,NA,"https://dx.doi.org/10.1007/s44197-022-00041-9","No asymptomatics"
"Russian Federation","Anton Barchuk","COVID-19 pandemic in Saint Petersburg, Russia: Combining population-based serological study and surveillance data.","Local","Journal Article (Peer-Reviewed)","Northwestern Region","Saint Petersburg","Eligible individuals were adults residing in St. Petersburg older than 18 years and recruited using the random digit dialling (RDD) method",NA,"All","2020-05-25","2020-06-28","Household and community samples","Multiple groups",988,0.097,0.077,0.117,"Simplified probability","CoronaPass total antibodies test","Genetico","ELISA","TotalAntibody","Spike","Validated by independent authors/third party/non-developers",0.92,1,"https://dx.doi.org/10.1371/journal.pone.0266945","No asymptomatics"
"Saudi Arabia","Sami Almudarra","High seroprevalence of SARS-CoV-2 among high-density communities in Saudi Arabia.","Local","Journal Article (Peer-Reviewed)",NA,NA,"A community-based serosurvey was carried out in three cities in Saudi Arabia. We asked the residents in these neighborhoods to participate voluntarily without any restrictions related to gender, age or nationality. In addition, we included those who
had prior positive SARS-CoV-2 PCR result, and had been
without symptoms for≥14 days, and also include those who
were never tested for SARS-CoV-2 and were asymptomatic.","We excluded symptomatic and those who were previously
labelled as COVID-19 cases and had not completed 14 days.","All","2020-08-01","2020-08-31","Household and community samples","Multiple groups",5629,0.502,0.488,0.515,"Simplified probability","Elecsys® Anti‐SARS‐CoV‐2 (N)","Roche Diagnostics","CLIA","IgG","Nucleocapsid(N-protein)",NA,NA,NA,"https://dx.doi.org/10.1007/s15010-021-01726-2","No asymptomatics"
"Singapore","Rei Kurohi","Coronavirus: Community transmission in  S'pore very low","Local","News and Media",NA,"Singapore",NA,NA,"All","2020-02-15","2020-04-15","Household and community samples","Multiple groups",774,0,NA,NA,"Unclear","Not reported/ Unable to specify",NA,NA,NA,NA,NA,NA,NA,"https://www.straitstimes.com/singapore/health/coronavirus-community-transmission-in-spore-very-low-but-so-is-herd-immunity-says","News and media"
"Singapore","Iain Tan","Prevalence and Outcomes of SARS-CoV-2 Infection Among Migrant Workers in Singapore","Local","Journal Article (Peer-Reviewed)","Singapore","Singapore","All migrant workers residing in a dormitory in purpose-build dormitories in Singapore.",NA,"All","2020-03-25","2020-07-25","Multiple populations","Adults (18-64 years)",135760,0.601,NA,NA,"Convenience","Atellica® IM SARS-CoV-2 Total (COV2T),Abbott Architect SARS-CoV-2 IgG,Elecsys® Anti‐SARS‐CoV‐2 (N)","Siemens,Abbott Laboratories,Roche Diagnostics","Multiple Types",NA,NA,NA,NA,NA,"https://dx.doi.org/10.1001/jama.2020.24071","No representation"
"South Africa","Jackie Kleynhans","SARS-CoV-2 Seroprevalence in a Rural and Urban Household Cohort during First and Second Waves of Infections, South Africa, July 2020-March 2021.","Local","Journal Article (Peer-Reviewed)","Mpumalanga Province","Bushbuckridge Municipality","Households that previously participated in the PHIRST study from 2017 and 2018 in the rural site cohort were approached for enrolment (located in the Bushbuckridge Municipality, Ehlanzeni District, Mpumalanga Province). Additional randomly selected households were eligible. Households with >3 household members of any age were enrolled if >80% of members consented.",NA,"All","2020-11-23","2020-12-12","Household and community samples","Multiple groups",568,0.07,0.05,0.09,"Simplified probability","Elecsys® Anti‐SARS‐CoV‐2 (N)","Roche Diagnostics","CLIA",NA,"Nucleocapsid(N-protein)","Validated by manufacturers",0.995,0.998,"https://dx.doi.org/10.3201/eid2712.211465","No asymptomatics"
"South Sudan","Kirsten E Wiens","Seroprevalence of severe acute respiratory syndrome coronavirus 2 IgG in Juba, South Sudan, 2020","Local","Journal Article (Peer-Reviewed)","Central Equatoria","Juba","We defined a household as a group of persons who slept under the same roof most nights and shared a cooking pot. Regardless of current or past COVID-19 illness, all household members were eligible for inclusion if they or their guardian provided written consent to participate and they were >1 year of age and had lived in the area >1 week before the survey. For households with >10 persons, only first-degree relatives of the head of household were eligible for study inclusion.  If multiple households lived in 1 shelter, we blindly drew from labeled papers to randomly select 1 household for inclusion.",NA,"All","2020-08-10","2020-09-11","Household and community samples","Multiple groups",2214,0.383,NA,NA,"Stratified probability","Author designed (ELISA) -Spike",NA,"ELISA","IgG","Spike","Validated by developers",0.655,1,"https://dx.doi.org/10.3201/eid2706.210568","No representation"
"Sweden","Stockholm Region","16 juli: Lägesrapport om arbetet med det nya coronaviruset","Local","Institutional Report","Uppland","Stockholm","Any resident wanting an antibody test. The tests are free of charge for the county's residents.",NA,"All","2020-06-15","2020-07-15","Household and community samples","Multiple groups",149616,0.176,NA,NA,"Self-referral","Not reported/ Unable to specify",NA,NA,NA,NA,NA,NA,NA,"https://www.sll.se/verksamhet/halsa-och-vard/nyheter-halsa-och-vard/2020/07/16-juli-lagesrapport-om-arbetet-med-det-nya-coronaviruset/","Institutional report"
"Sweden","The Local","14% of coronavirus antibody tests positive in Sweden in July","Local","News and Media","Skåne, Västra Götaland, Uppland","Stockholm, Gothenburg, Malmo","Residents of Malmo, Gothenburg, and Stockholm.",NA,"All","2020-07-01","2020-07-22","Household and community samples","Multiple groups",83000,0.144,NA,NA,"Unclear","Not reported/ Unable to specify",NA,NA,NA,NA,NA,NA,NA,"https://www.google.com/url?rct=j&sa=t&url=https://www.thelocal.se/20200723/14-of-antibody-tests-positive-in-sweden&ct=ga&cd=CAAYBzIaOTBkZWE5ODk5NGU5MTg1OTpjb206ZW46VVM&usg=AFQjCNHl1If-XI0aCeB5tGakbaJvFktByQ","News and media"
"Sweden","The Stockholm Region","25 september: Lägesrapport om arbetet med det nya coronaviruset","Local","Institutional Report",NA,"Stockholm",NA,NA,"All","2020-06-15","2020-09-20","Household and community samples","Multiple groups",483345,0.152,NA,NA,"Unclear","Not reported/ Unable to specify",NA,NA,NA,NA,NA,NA,NA,"https://www.sll.se/verksamhet/halsa-och-vard/nyheter-halsa-och-vard/2020/09/25-september-lagesrapport-om-arbetet-med-det-nya-coronaviruset/","Institutional report"
"Sweden","The Stockholm Region","29 september: Lägesrapport om covid-19","Local","Institutional Report",NA,"Stockholm",NA,NA,"All","2020-09-21","2020-09-27","Household and community samples","Multiple groups",9648,0.143,NA,NA,"Unclear","Not reported/ Unable to specify",NA,NA,NA,NA,NA,NA,NA,"https://www.sll.se/verksamhet/halsa-och-vard/nyheter-halsa-och-vard/2020/09/29-september-lagesrapport-om-covid-19/","Institutional report"
"Sweden","The Stockholm Region","6 oktober: Lägesrapport om covid-19","Local","Institutional Report",NA,"Stockholm",NA,NA,"All","2020-09-28","2020-10-04","Household and community samples","Multiple groups",11670,0.154,NA,NA,"Unclear","Not reported/ Unable to specify",NA,NA,NA,NA,NA,NA,NA,"https://www.sll.se/verksamhet/halsa-och-vard/nyheter-halsa-och-vard/2020/10/6-oktober-lagesrapport-om-covid-19/","Institutional report"
"Sweden","The Stockholm Region","13 oktober: Lägesrapport om covid-19","Local","Institutional Report",NA,"Stockholm",NA,NA,"All","2020-10-05","2020-10-11","Household and community samples","Multiple groups",11065,0.152,NA,NA,"Unclear","Not reported/ Unable to specify",NA,NA,NA,NA,NA,NA,NA,"https://www.sll.se/verksamhet/halsa-och-vard/nyheter-halsa-och-vard/2020/10/13-oktober-lagesrapport-om-covid-19/","Institutional report"
"Sweden","The Stockholm Region","20 oktober: Lägesrapport om covid-19","Local","Institutional Report",NA,"Stockholm",NA,NA,"All","2020-10-12","2020-10-18","Household and community samples","Multiple groups",10297,0.154,NA,NA,"Unclear","Not reported/ Unable to specify",NA,NA,NA,NA,NA,NA,NA,"https://www.sll.se/verksamhet/halsa-och-vard/nyheter-halsa-och-vard/2020/10/20-oktober-lagesrapport-om-covid-19/","Institutional report"
"Sweden","The Stockholm Region","27 oktober: Lägesrapport om covid-19","Local","Institutional Report",NA,"Stockholm",NA,NA,"All","2020-10-19","2020-10-25","Household and community samples","Multiple groups",8941,0.206,NA,NA,"Unclear","Not reported/ Unable to specify",NA,NA,NA,NA,NA,NA,NA,"https://www.sll.se/verksamhet/halsa-och-vard/nyheter-halsa-och-vard/2020/10/27-oktober-lagesrapport-om-covid-19/","Institutional report"
"Sweden","The Stockholm Region","3 november: Lägesrapport om covid-19","Local","Institutional Report",NA,"Stockholm",NA,NA,"All","2020-10-26","2020-11-01","Household and community samples","Multiple groups",9580,0.217,NA,NA,"Unclear","Not reported/ Unable to specify",NA,NA,NA,NA,NA,NA,NA,"https://www.sll.se/verksamhet/halsa-och-vard/nyheter-halsa-och-vard/2020/11/3-november-lagesrapport-om-covid-19/","Institutional report"
"Sweden","The Stockholm Region","10 november: Lägesrapport om covid-19","Local","Institutional Report",NA,"Stockholm",NA,NA,"All","2020-11-02","2020-11-08","Household and community samples","Multiple groups",11500,0.259,NA,NA,"Unclear","Not reported/ Unable to specify",NA,NA,NA,NA,NA,NA,NA,"https://www.sll.se/verksamhet/halsa-och-vard/nyheter-halsa-och-vard/2020/11/10-november-lagesrapport-om-covid-19/","Institutional report"
"Sweden","The Stockholm Region","17 november: Lägesrapport om covid-19","Local","Institutional Report",NA,"Stockholm",NA,NA,"All","2020-11-09","2020-11-15","Household and community samples","Multiple groups",13273,0.278,NA,NA,"Unclear","Not reported/ Unable to specify",NA,NA,NA,NA,NA,NA,NA,"https://www.sll.se/verksamhet/halsa-och-vard/nyheter-halsa-och-vard/2020/11/17-november-lagesrapport-om-covid-19/","Institutional report"
"Sweden","The Stockholm Region","24 november: Lägesrapport om covid-19","Local","Institutional Report",NA,"Stockholm",NA,NA,"All","2020-11-16","2020-11-22","Household and community samples","Multiple groups",15474,0.314,NA,NA,"Unclear","Not reported/ Unable to specify",NA,NA,NA,NA,NA,NA,NA,"https://www.sll.se/verksamhet/halsa-och-vard/nyheter-halsa-och-vard/2020/11/24-november-lagesrapport-om-covid-19/","Institutional report"
"Sweden","The Stockholm Region","1 december: Lägesrapport om covid-19","Local","Institutional Report",NA,"Stockholm",NA,NA,"All","2020-11-23","2020-11-29","Household and community samples","Multiple groups",16389,0.336,NA,NA,"Unclear","Not reported/ Unable to specify",NA,NA,NA,NA,NA,NA,NA,"https://www.sll.se/verksamhet/halsa-och-vard/nyheter-halsa-och-vard/2020/12/1-december-lagesrapport-om-covid-19/","Institutional report"
"Sweden","The Stockholm Region","8 december: Lägesrapport om covid-19","Local","Institutional Report",NA,"Stockholm",NA,NA,"All","2020-11-30","2020-12-06","Household and community samples","Multiple groups",16943,0.367,NA,NA,"Unclear","Not reported/ Unable to specify",NA,NA,NA,NA,NA,NA,NA,"https://www.sll.se/verksamhet/halsa-och-vard/nyheter-halsa-och-vard/2020/12/8-december-lagesrapport-om-covid-19/","Institutional report"
"Sweden","The Stockholm Region","15 december: Lägesrapport om covid-19","Local","Institutional Report",NA,"Stockholm",NA,NA,"All","2020-12-07","2020-12-13","Household and community samples","Multiple groups",20466,0.39,NA,NA,"Unclear","Not reported/ Unable to specify",NA,NA,NA,NA,NA,NA,NA,"https://www.sll.se/verksamhet/halsa-och-vard/nyheter-halsa-och-vard/2020/12/15-december-lagesrapport-om-covid-19/","Institutional report"
"Sweden","The Stockholm Region","22 december: Lägesrapport om covid-19","Local","Institutional Report",NA,"Stockholm",NA,NA,"All","2020-12-14","2020-12-20","Household and community samples","Multiple groups",23466,0.381,NA,NA,"Unclear","Not reported/ Unable to specify",NA,NA,NA,NA,NA,NA,NA,"https://www.sll.se/verksamhet/halsa-och-vard/nyheter-halsa-och-vard/2020/12/22-december-lagesrapport-om-covid-19/","Institutional report"
"Sweden","The Stockholm Region","29 december: Lägesrapport om covid-19","Local","Institutional Report",NA,"Stockholm",NA,NA,"All","2020-12-21","2020-12-27","Household and community samples","Multiple groups",17624,0.378,NA,NA,"Unclear","Not reported/ Unable to specify",NA,NA,NA,NA,NA,NA,NA,"https://www.sll.se/verksamhet/halsa-och-vard/nyheter-halsa-och-vard/2020/12/29-december-lagesrapport-om-covid-19/","Institutional report"
"Sweden","Niclas Roxhed","Multianalyte serology in home-sampled blood enables an unbiased assessment of the immune response against SARS-CoV-2.","Local","Journal Article (Peer-Reviewed)",NA,"Stolkholm","2000 randomly selected inhabitants (20–74 years old) from the population register in metropolitan Stockholm (Table S3) during April 2020.",NA,"All","2020-04-15","2020-05-15","Household and community samples","Multiple groups",878,0.125,0.103,0.147,"Simplified probability","Author designed (Luminex)",NA,"ELISA","['IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']","Validated by developers",1,0.96,"https://dx.doi.org/10.1038/s41467-021-23893-4","No representation"
"Thailand","Hatairat Lerdsamran","Seroprevalence of anti-SARS-CoV-2 antibodies in Thai adults during the first three epidemic waves.","Local","Journal Article (Peer-Reviewed)",NA,"Bangkok, Chiang Mai","Thai citizens in state quarantines, who had arrived in Thailand after extended periods of work in countries with known SARS-CoV-2 outbreaks.",NA,"All","2020-05-17","2020-10-12","Multiple populations","Adults (18-64 years)",553,0.28,0.2379,0.328,"Unclear","Author designed (Neutralization Assay),Abbott Architect SARS-CoV-2 IgG,Author designed (IFA) - MULTIPLEXED","NA,Abbott Laboratories","Multiple Types","['IgA', 'IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",NA,NA,NA,"https://dx.doi.org/10.1371/journal.pone.0263316","No representation"
"Ukraine","Alla Marchenko","EPIDEMIOLOGICAL DATA ON THE DETECTION OF IMMUNOGLOBULINS OF CLASS IGM, IGG TO SARS-COV-2 AMONG POPULATION OF POLTAVA REGION.","Local","Journal Article (Peer-Reviewed)","Poltava Oblast","Poltava",NA,NA,"All","2020-07-15","2020-12-15","Household and community samples","Multiple groups",2375,0.057,NA,NA,"Self-referral","EQUI SARS-CoV-2 IgM","EKVITESTLAB LLC","ELISA","IgG",NA,NA,NA,NA,"https://wiadlek.pl/wp-content/uploads/archive/2021/WLek202105116.pdf","No asymptomatics"
"Yemen","Abdulla Bin-Ghouth","SARS-CoV-2 seroprevalence in Aden, Yemen: a population-based study","Local","Journal Article (Peer-Reviewed)","Adan Governorate","Aden","Residents of Aden",NA,"All","2020-11-15","2020-12-15","Household and community samples","Multiple groups",2001,0.274,0.256,0.293,"Stratified probability","COVID-19 IgG/IgM Rapid Test Cassette,Wantai SARS-CoV-2 Total Ab ELISA","Healgen,Beijing Wantai Biological","Multiple Types","['IgG', 'IgM']","Spike",NA,NA,NA,"https://dx.doi.org/10.1016/j.ijid.2021.12.330","No representation"
"Zimbabwe","Arun Fryatt","Community SARS-CoV-2 seroprevalence before and after the second wave of SARS-CoV-2 infection in Harare, Zimbabwe.","Local","Journal Article (Peer-Reviewed)","Harare","Harare","randomly selected households aiming for a total of 2000 participants in three communi- ties in Harare namely Budiriro, Highfield and Mbare

Individuals of any age who had slept three out of the last seven nights in the household before the survey team visited were eligible for participation in the survey.",NA,"All","2020-11-20","2020-12-20","Household and community samples","Multiple groups",620,0.19,0.151,0.235,"Simplified probability","Author designed (type unknown)",NA,"Other",NA,"Nucleocapsid(N-protein)","Validated by developers",0.992,0.9865,"https://dx.doi.org/10.1016/j.eclinm.2021.101172","No asymptomatics"
"occupied Palestinian territory - including east Jerusalem","Nouar Qutob","Seroprevalence of SARS-CoV-2 in the West Bank region of Palestine: a cross-sectional seroepidemiological study","Local","Journal Article (Peer-Reviewed)",NA,"West Bank","non-institutionalised Palestinian population residing in the West Bank","The random sample did not include children under the age of 15","All","2020-06-15","2020-06-30","Household and community samples","Multiple groups",1355,0,0,0.0043,"Stratified probability","Elecsys® Anti‐SARS‐CoV‐2 (N)","Roche Diagnostics","CLIA","TotalAntibody","Nucleocapsid(N-protein)","Validated by independent authors/third party/non-developers",0.8387,1,"https://bmjopen.bmj.com/content/11/2/e044552","No representation"
